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This thesis is constructed of four chapters: 
 Chapter one comprises a general introduction to malaria, 
with emphasis on the host immune responses during an infection, 
and the usage of mouse models in Experimental Cerebral malaria. 
This chapter also includes the thesis objectives. 
 Chapter two presents the development and results of a 
novel cell transfer protocol designed during this thesis work. 
 Chapter three includes the manuscript comprising my Ph.D. 
thesis work, accepted for publication. 
Chapter two and three are comprised of author 
contributions, summary and introduction, detailed material and 
methods, with results and discussion. 
Chapter four comprises the general discussion for this 
thesis work, including conclusions and future prospectives. 
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Summary 
 
Cerebral malaria is a severe and fatal form of clinical Plasmodium 
falciparum infection, resulting in brain injury from a damaging 
cascade of vascular, inflammatory and immunological host 
responses. However progression to cerebral malaria can be 
modified by host genetic factors. This thesis work extensively 
reveals the role of Interferon type I receptor (IFNAR1) in the 
development of Experimental cerebral malaria, through the use of 
the mouse model Ifnar1-/-. We found Ifnar1-/- mice protected from 
Experimental cerebral malaria upon infection with Plasmodium 
berghei ANKA-GFP, compared with susceptible wild-type C57BL/6 
mice. Ifnar1-/- mice showed diminished blood brain barrier breakage, 
despite parasite accumulation in the periphery and accumulation of 
immune cells within the brain tissue during infection. To elucidate 
the cellular basis of Ifnar1-/- resistance we developed a novel cell 
transfer protocol that enables spleen cell priming in absence of 
disease. This further led us to discover that IFNAR1 expression in 
CD8+ T cells is crucial, and can abrogate resistance to 
Experimental cerebral malaria in Ifnar1-/- mice. We found splenic 
CD8+ T cells from Ifnar1-/- mice are functionally activated upon 
infection, yet unable to mediate Experimental cerebral malaria 
development within the brain tissue.  
Our findings prove that IFNAR1 signaling unleashes CD8+ T cell 
effector capacity, vital for cerebral malaria and concludes the 
essential role of IFNAR1 in CD8+ T cell triggering. Moreover this 
suggests a possible role of CD8+ T cells in human cerebral malaria 
development, and highlights IFNAR1 as a potential therapeutic 
target in future preventative measures against cerebral malaria.   
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Sumário 
 
A malária  cerebral é uma forma clínica severa e fatal da infecção  
por Plasmodium falciparum, que causada por uma cadeia de 
respostas vasculares, inflamatórias e imunológicas que 
determinam lesões cerebrais. O risco de ocorrência de malária 
cerebral em indivíduos infectados está dependente de factores 
genéticos. Esta tese revela o papel do gene IFNAR1 (receptor 1 do 
interferão alpha) num modelo experimental de malária cerebral, 
pela análise de ratinhos Ifnar1-/-. Os ratinhos Ifnar1-/- demonstraram 
resistência à indução de malária cerebral por Plasmodium berghei 
ANKA-GFP. Os ratinhos Ifnar1-/- infectados mostraram reduzida 
incidência de quebra da barreira hemato-encefálica apesar de 
mostrarem acumulação de eritrócitos parasitados e de células do 
sistema imunitário no tecido cerebral. Para determinar a base 
celular da resistência à malária cerebral nos ratinhos Ifnar1 -/- 
desenvolvido um protocolo de transferência celular que impede a 
transferência simultânea do parasita quando são transferidas 
células esplénicas que foram desfiadas pelo parasita. Este 
protocolo permitiu evidenciar que a expressão de IFNAR1 nas 
células CD8+ é crucial e é suficiente para induzir malária cerebral 
nos ratinhos Ifnar1 -/-.  As células T CD8+ dos ratinhos Ifnar1-/-  
infectados revelaram estar funcionalmente activadas mas 
incapazes de provocarem cerebral malária. 
Este trabalho mostra que a sinalização pelo IFNAR1 acciona a 
capacidade efectora das células T CD8+ é critico para o 
desenvolvimento da malária cerebral. Este trabalho propõe um 
papel relevante para o gene IFNAR1 no desenvolvimento da 
malária cerebral em seres humanos e sugere o IFNAR1 como um 
potencial alvo terapêutico na prevenção da malária cerebral. 
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1.1 Epidemiology and Malaria infection. 
1.1.1 Epidemiology 
! Research into malaria first began through the work of Ettore 
Marchiafava and Amico Bignami in 1890’s (Autino et al., 2012). 
They were amongst the first to recognize that the cause of malaria 
could be transported through the mosquito, and Marchiafava 
named this parasite, Plasmodium. Plasmodium is a protozoan 
parasite (Sinnis and Zavala, 2012), of which there are four species 
that infect humans, P. ovale; P. vivax; P. malariae; and P. 
falciparum (Haldar et al., 2007), and most recently  a fifth species 
now found to infect humans, P.knowlesi (Servonnet et al., 
2012).The parasite Plasmodium falciparum has been classed as 
one of the most successful human pathogens (Urban et al., 1999). 
Malaria was first recorded in around 2700 BC in ancient Chinese 
texts, and yet Plasmodium still fathoms research by its evading 
capacities and no effective cure has been found to date. 
Plasmodium also continues to challenge strategies of elimination 
and eradication and procure successfully both the human and 
mosquito host.  
 More than 40% of the world’s population is at risk of 
infection by Plasmodium parasites, with roughly 216 million cases 
of malaria being recorded in 2010 (WHO report, 2012). 
P.falciparum infections are mainly responsible for cases leading to 
severe malaria (Rosenthal, 2008), a complicated and severe form, 
which presents with clinical manifestations including, anemia; 
hypoglycemia; metabolic acidosis; repeated seizures; coma and 
multiple organ failure (Snow et al., 2005). One % of severe cases of 
infection can further develop into Cerebral malaria (CM) (de Souza 
et al., 2010), a clinical form of severe malaria dominated by a 
! #$!
neurological syndrome, and occurs within the incidence of 1-1.2 
million cases/year, in endemic regions of Africa (Idro et al., 2010), 
with up to 20% of cases being fatal (Idro et al., 2005). Its peak 
incidence is in children under 5 years of age, and approximately 
500,000-800,000 children develop CM each year in sub Saharan 
Africa alone (Reis et al., 2012). Economically, the 213 million 
annual ‘attacks’ of malaria, has led to over 800 million sick days 
being taken per year in Africa (Breman et al., 2004), thus showing 
what a catastrophic effect malaria infections cause in endemic 
countries. 
 
1.1.2 Lifecycle of Malaria infection 
 The Plasmodium parasite is transmitted through the bite of 
an infected female Anopheles mosquito, as well as a yet 
unclassified species of mosquito recently found (Stevenson et al., 
2012). Female mosquitoes seek a human blood meal for 
fertilization of their eggs. During this piercing of the skin, the 
parasite passes through the saliva of the mosquito and is deposited 
in the skin of the human, now classified as a host. The initial 
deposit within the dermis, is then followed by gliding of the 
sporozoites to the bloodstream in which it is transported to the liver, 
an obligatory stage of development (Prudencio et al., 2006). 
Infection in the human host occurs in two phases, the first 
asymptomatic liver stage and the second blood stage of infection 
that is often symptomatic. Following passage in the liver sinusoids, 
individual sporozoites traverse a number of hepatocytes before 
residing in the hosting hepatocyte where they expand and develop 
into merozoites (Sturm et al., 2006). Merozoites are released from 
infected hepatocytes inside vesicles termed merosomes, into the 
!#%!
blood stream, where they invade red blood cells and follow a 
second stage of asexual development (Liehl and Mota, 2012). 
Infected red blood cells (iRBC), eventually rupture and release 
daughter merozoites that then can invade fresh erythrocytes 
(Haldar et al., 2007). This process of iRBC bursting and invasion 
occurs cyclically every 48 hours, triggering host immune responses 
and causes the onset of fever, sweating and chills (Sinnis and 
Zavala, 2012), the first apparent symptoms of a malaria infection. P. 
falciparum is unique in its cycle, whereby every 24-32 hours, upon 
maturation into its trophozoite (ring) stage, iRBC can then adhere to 
endothelial cells in the circulation of particular organs, such as liver, 
placenta and brain (Haldar et al., 2007). A select number of 
parasites within iRBC can differentiate into male and female 
gametocytes, which are taken up by a feeding mosquito (Michalakis 
and Renaud, 2009), and undergo sexual development within the 
mosquito to form sporozoites within the mid-gut, ready to be 
deposited in the next blood meal and thereby completing the 
parasite lifecycle. The passage between the human host and 
mosquito vector leads to loss of parasite numbers but the asexual 
and sexual replication within the human and mosquito, ensures 
expansion of these numbers (Sinnis and Zavala, 2012), and a 
successful transmission. Figure 1.1 represents an example of the 
malaria lifecycle.  
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Figure 1.1 Malaria lifecycle of P.falciparum (van Agtmael et al., 
1999).. From the bite of an infected female Anopheles mosquito, 
sporozoites are transmitted through the salivary glands into the 
blood stream of the human host. They migrate to the liver where 
they traverse and then reside in hepatocytes, within one hour of 
infection. Sporozoites develop asexually into merozoites. Within 5-7 
days after initial infection, infected hepatocytes release thousands 
of merozoites, which then invade red blood cells. The parasite 
further develops within red blood cells, and every 48 hours mature 
schizonts are released by rupture of infected red blood cells into the 
bloodstream, where they are available to invade fresh red blood 
cells. This cyclical rupture leads to the host immune responses and 
development of malaria symptoms, such as high fever and chills. 
(Adapted and re-printed with author permission). 
 
1.1.3 Clinical disease 
! Malaria cases present with fever and chills along with 
common symptoms of dizziness; diarrhea; nausea; vomiting and 
dry cough (Trampuz et al., 2003), however there is great difficulty in 
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clinical diagnosis and treatment for malaria as often these 
symptoms appear flu-like (Murphy and Oldfield, 1996). Severe and 
complicated malaria is characterized by anaemia; hypoglycemia; 
respiratory distress; altered consciousness and general malaise 
and can progress to major complications, including pulmonary 
edema; acute renal failure; multi-organ failure and cerebral malaria 
(CM) (de Souza et al., 2010; Haldar et al., 2007).  
Severe anemia from malaria infection accounts for a large 
proportion of deaths in children living in endemic regions of Africa 
(Murphy and Breman, 2001). Anemia has been primarily linked to 
the bursting of iRBC, and the clearance of deformed RBC from the 
circulation (Haldar and Mohandas, 2009). The role that the spleen 
plays in malaria infection is also extensive, and enlargement of the 
spleen (splenomegaly) is often seen during infection (Ahmed et al., 
2011). It has been claimed that the spleen can work as a ‘double-
edged sword’ in malaria, harbouring  both non-infected and iRBC, 
which can lead to a decrease in total body parasite burden, 
therefore decreasing the risk of progression to CM, but at the same 
time increasing the risk of severe malaria anemia (Buffet et al., 
2009).  
 Measurement of peripheral parasitemia is the most 
common method in diagnosing a malaria infection. It might be 
thought that the higher the levels of parasite in the body, the 
increased risk of developing a severe form of the disease. This is 
often the argument for human CM cases, however a clinical study 
did find 7 out of 31 cases of P.falciparum CM without high levels of 
pRBS in the brain tissue (Taylor et al., 2004), and that further cases 
of hyperparasitemia (high levels of parasitemia) have been 
recorded in non-CM patients also (Craig et al., 2012).  
! #(!
In the case of the mouse model, recent work by (Haque et 
al., 2011a) stated that early immune responses, primarily led by 
CD4+ T cells, aimed at decreasing parasite burden and predicts 
disease severity and risk of death. However work by (McQuillan et 
al., 2011) found that treatment with anti-malaria quinine protected 
mice from ECM development, despite increase in peripheral 
parasitemia. Therefore it is still not confirmed whether levels of 
parasitemia can be used in predicting disease outcome. 
 
1.2 Cerebral Malaria 
 In P.falciparum cases of malaria, roughly 1% of these 
develop into the severe form of CM, with  10-20% of these cases 
having a fatal outcome in the absence of treatment, translating into 
roughly 300,000-500,000 deaths per year (de Souza et al., 2010). 
CM develops very rapidly, in the case of a few hours, following the 
initial days of fever from the blood stage of infection.  
The only recognized form of clinical diagnosis for CM is 
unarousable coma, not attributed to other causes, defined by the 
World Health Organization (WHO) (Molyneux et al., 1989; Teasdale 
and Jennett, 1974). Further symptoms of CM can include general 
malaise; headaches; fits and vomiting and diarrhea (de Souza et 
al., 2010; Newton and Krishna, 1998) and these early symptoms of 
CM can quickly progress to increases in intracranial pressure; 
paralysis; ataxia and coma (de Souza et al., 2010). The clinical 
presentation of CM can vary widely amongst patients, making it 
very hard to distinguish from other neurological diseases. This 
difficulty in diagnosis, combined with the poor treatment options, 
begs for early resolutions at catching the onset of CM in malaria 
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cases. Even CM cases that received treatment with anti-malaria 
drugs, Artemisinin and quinine, resulted in death in 15% and 22% 
of the cases (Dondorp et al., 2005). Therefore it is imperative that 
research continues to devour the triggers and preventative 
measures of CM development.  
 
1.2.1 Host genotype and malaria infection 
! Treatment options for malaria are limited to anti-parasite 
drugs selected at targeting and diminishing the blood stage of 
infection and its symptoms. Therefore in endemic areas of malaria, 
due to the lack of knowledge and protection against the initial 
(silent), liver stage of disease, a person can be re-exposed to 
infections throughout life (Aidoo and Udhayakumar, 2000). Even 
after effective anti-malaria treatment for cerebral malaria (CM), 
patients can still suffer long term neurological sequellae (Shikani et 
al., 2012). Therefore after apparent elimination of the parasite this 
does not resolve the clinical consequences of an infection and 
furthermore the process of parasite re-exposure can lead to long-
term influences on human genetics.  
Genetic risk factors for severe malaria have shown that 
roughly 25% of the risk in progressing to a severe form of malaria is 
determined by human genetic factors (Mackinnon et al., 2005; Rihet 
et al., 1998). For our interests, further evidence indicates from both 
human and mouse model studies of CM, that host-genetic 
components influence the outcome of CM, and that this outcome 
may be polygenic (Driss et al., 2011; Hunt et al., 2006; Sambo et 
al., 2010). 
Further genetic variants associated with CM risk include 
polymorphisms in the N-terminal region of I-CAM1, found to 
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increase risk of CM in African populations (Craig et al., 2000); 
single-nucleotide-polymorphisms (SNPs) encoding IL-13 were 
found in a Tanzanian population to increase the risk of CM 
(Manjurano et al., 2012); SNPs in Interferon-alpha receptor-1 
(IFNAR1) gene show protection against CM (Aucan et al., 2003); 
polymorphisms in the promoter region of the Interferon-gamma 
receptor-1 (IFGR1) gene are associated with CM susceptibility 
(Koch et al., 2002)  and polymorphisms in the promoter region of 
the TNF gene, have been found to increase risk of neurological 
symptoms in Gambian children (McGuire et al., 1994; McGuire et 
al., 1999). The polymorphism in the TNF2 allele, although 
disadvantageous for severe malaria anaemia risk, is still carried 
within the population suggesting it is biologically advantageous, 
which may represent a balancing selection phenomenon also 
associated with the sickle cell anemia gene (Ferreira et al., 2011).  
A recent report also suggests that host variation interplays 
with infection and that genetic variation in children pre-disposes 
them in mounting an effective immune response towards a malaria 
infection (Idaghdour et al., 2012). Collectively, these studies provide 
genetic links to CM susceptibility, and have begun to pinpoint 
inflammatory mediators that influence the development of CM. 
Therefore it is crucial in CM research to decipher the role of these 
mediators within common pathogenic mechanisms leading to CM 
development. 
 
1.2.2 Mouse model vs Human cases 
 There is a large debate in the field of malaria research to the 
advantages behind the use of mouse models in CM research. I 
believe this will always be a hot topic, and so it is imperative that 
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researchers focus on how the mouse model can help us 
understand  human cases of CM development.  
One published article on human vs mouse models caused 
debate when it stated that the model of Plasmodium berghei ANKA 
(PbA) was limited in its use for understanding the pathogenesis of 
human CM (White et al., 2010). It was met with much dispute by 
leading researchers who use the mouse model, termed 
Experimental cerebral malaria (ECM). Together they support the 
essential role the mouse model contributes in CM understanding 
(Carvalho, 2010; de Souza et al., 2010; Renia et al., 2010; Riley et 
al., 2010). In particular Carvalho and colleagues and Hunt and 
colleagues, (Carvalho, 2010; Hunt et al., 2010) raise the issue of 
decreased publications of human CM cases, and express concerns 
that researchers should focus on the similarities between the 
mouse and human models and how essential discoveries were 
made by the mouse model for human studies. The example of our 
recently published article in Chapter three, is one such paper that 
led from the discovery of genetic polymorphisms amongst human 
patients, to the understanding and discovering of IFNAR1 roles in 
CM through the use of ECM mouse models.   
The apparent controversial difference lies between human 
CM development being caused by sequestration of pRBC vs mouse 
ECM being a consequence of leukocyte sequestration (Cabrales et 
al., 2010; Craig et al., 2012).  However autopsies from a small 
number of human cases that died from severe malaria, with no CM, 
have shown signs of sequestration of pRBC within the brain 
(Pongponratn et al., 2003). Furthermore, as P.falciparum is the only 
human parasite species that sequesters within the brain and the 
main species that causes CM development (Sarkar and 
Bhattacharya, 2008), these cases suggest pRBC sequestration 
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may not be the determining factor for human CM development 
(Pino et al., 2005). Given that human and mouse CM both occur 
through obstruction of micro-vessels within the brain tissue, by 
pRBC or leucocytes or both, this could represent a common 
mechanism in CM development (Craig et al., 2012). In support 
iRBC have been imaged within post-capillary venules in 
P.falciparum infections, as seen in ECM (Dondorp et al., 2004; 
Nacer et al., 2012) 
Two main hypotheses exist for the cause of CM in human 
cases (Hunt et al., 2006). The mechanical obstruction hypothesis 
whereby CM is a consequence of parasitized (p)RBC adhering to 
endothelial cells, leading to vascular obstruction and cerebral 
oxygen deprivation (hypoxia) (Berendt et al., 1994), opposed to the 
cytokine response hypothesis that supports a central role for 
cytokines in CM immuno-pathology (Clark and Rockett, 1994). 
Therefore the ECM model is also currently used to investigate the 
role of cytokines in ECM development.   
The largest advantage of the mouse model is the ability of 
researchers to closely examine the brain tissue during CM 
occurrence, a limiting factor in human case studies. Knockout 
strains of mice as well as genetically altered mouse strains have 
been instrumental in exploring in-depth potential inflammatory and 
immune regulatory mechanisms that lead to ECM development 
(Grau et al., 1986; Pamplona et al., 2007; Parekh et al., 2006; 
Serghides et al., 2011; Zhu et al., 2012). In conclusion it is of the 
role of the researcher to provide an appropriate experimental 
system that aims at deepening our understanding of human CM 
cases, rather than distancing the gap between the human and 
mouse models.  
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1.2.3 Experimental Cerebral Malaria pathogenesis 
 Consistent with human studies of CM, genetic background, 
age, degree of infection and clonal variations in parasite strains, all 
play a role in the pathogenesis of Experimental Cerebral Malaria 
(ECM) (de Souza et al., 2010; Lackner et al., 2006). 
Infections with the PbA strain of parasite, together with the C57BL/6 
mouse strain, has set up an established susceptible mouse model 
for ECM (Rest, 1982), and this model is accepted as the most 
available experimental model, replicating many events seen during 
human CM (de Souza et al., 2010).  
Mice develop symptoms of ECM between days 5-7 post-
infection, expressing relatively low parasitemia levels and die within 
2-3 days from disease onset. Symptoms of ECM include ataxia; 
convulsions; roll over; paralysis and coma (de Souza et al., 2010; 
Favre et al., 1999; Lackner et al., 2006). However not all of these 
symptoms are consistently found in the disease state, and as like 
human cases, there is variation also (Linares et al., 2012).  
A well-documented account of ECM development, and its 
neurological events has been reported by Lackner and colleagues 
(Lackner et al., 2006). This has helped record the pathogenic 
events leading up to ECM, and more importantly provide a 
framework to evaluate how these events correlate to a human 
infection. After the onset of neurological symptoms, a decrease in 
body temperature is seen in the mice – a reliable indicator of 
terminal illness - 36 hours prior to death, motor functions and co-
ordination are lost and respiratory rate becomes altered, which is 
consistent with brainstem lesions. General muscle tone and 
strength is lost and this can be used as a good marker to 
distinguish ECM from non-ECM mice also.  
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It can be difficult to assess symptoms of ECM, alike clinical 
diagnosis of human CM. The SHIRPA score was developed to 
mimic the general, neurological and psychological assessments 
used in human cases (Rogers et al., 1997). The score produces 
quantitative data for each mouse at three different stages of 
cerebral disease, collectively giving a specific profile of the mouse 
related to loss of function. It is not a widespread or mandatory form 
of ECM assessment, but it has been suggested as useful to 
document the beginning stages of cerebral disease (Lackner et al., 
2006), and does allow for abnormalities between mouse strains to 
be detected (Rogers et al., 1997). A similar score for ECM 
assessment has also been documented, a quantitative, rapid 
murine coma and behavioural score (RMCBS) (Carroll et al., 2010). 
This score was developed to assess ECM in the PbA mouse model, 
aimed at identifying symptoms preceding ECM onset, for use in 
potential treatment trials. Together these assessments and the 
experience of the researcher are the standard diagnostic 
procedures used for ECM models.  
 
1.2.4 Brain tissue damage  
! The general assessment for brain tissue damage in mice is 
through analysis of brain sections and by evaluating the level of 
permeability and leakage of the blood brain barrier (BBB). Brain 
tissue damage by cerebral malaria development has been found to 
include disruption of vessel walls; endothelial degeneration and 
cerebral edema, as well as adherence of pRBC and blood 
leucocytes in brain vessels (Lackner et al., 2006). 
Many authors questioned whether there is a specific area of 
the brain that is  affected most during malaria. The work of (Lackner 
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et al., 2006) found that lesions were most significant in the 
forebrain, brain stem, with most damage seen in the 
rhinencephalon area. In a study with Malawian children areas of 
vascular damage in the brain also showed myelin loss and axonal 
damage (Dorovini-Zis et al., 2011), further verified in adult 
Vietnamese populations (Medana et al., 2002). However unless the 
research study is focused upon identifying lesions or damage to the 
brain, this is not a specific objective in CM assessment, and a 
general concensus is that there is no one specific area of damage 
within the brain cortex of mice or human cases of CM.  
 
1.2.4.1 Blood brain barrier  
 Blood brain barrier (BBB) breakage is a hallmark of ECM, 
however it is not generally seen in human cases of CM (Clark et al., 
1992).  Breakage of the BBB is confirmed only after death, through 
experimental in vivo injection of dye into the circulation and followed 
by anatomical analysis (Favre et al., 1999). The exact point at 
which breakage of the barrier occurs is much a question of whether 
ECM development leads to BBB breakage, or if BBB breakage is 
the cause of ECM progression. 
The BBB is described as a selective barrier formed by 
endothelial cells (EC) that line the brain microvasculature (Abbott et 
al., 2006). There are in fact three types of barriers, the physical 
barrier, made up of tight junctions between the EC; a transport 
barrier between the luminal and subluminal membranes of the EC, 
controlling the entry of essential and harmful molecules into the 
brain and a metabolic barrier, governed by intra and extracellular 
enzymes (Abbott et al., 2006). Together these barriers regulate the 
homeostasis of the brain and keep it guarded and selectively 
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separate from the body. In this way brain interstitial fluid (ISF), 
which bathes the brain cells is maintained at optimal conditions for 
neuronal function.  
The BBB is found predominantly in the brain capillaries, but 
there are also more modulatory barriers within the arterioles and 
venules of the brain (Abbott et al., 2006). Figure 1.2 shows the 
makeup of the BBB. Within this figure there is also note of astrocyte 
cells, the brain perivascular cells that help to regulate the BBB 
function (Abbott et al., 2006), enhancing protection and avoidance 
of un-necessary compound entry into the brain parenchyma.  
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Figure 1.2. The blood brain barrier (BBB). (Francis et al., 2003). 
The BBB is created by tight junctions of EC that line the blood 
vessels within the brain, forming a barrier between the circulation 
and brain parenchyma. Lymphocytes, monocytes and neutrophils 
(blood-borne cells) cannot penetrate the barrier. The thin basement 
membrane also adds mechanical support, aiding the barrier 
function, it is made up of lamin, fibronectin and other proteins and 
surrounds the EC and pericytes. The BBB is critical in preventing 
pathogen and antibody entry into the CNS, protecting the brain 
tissue from inflammatory damage due to immune responses. 
(Adapted and re-printed with authors permission). 
 
 Endothelial cells and astrocytes themselves form a close 
barrier, supporting each other in correcting cellular associations 
between EC and pericytes, and the EC support growth and 
differentiation of the astrocytes (Abbott et al., 2006). EC are 
supported further by pericytes, cells that wrap themselves around 
the EC and occupy a key position (Armulik et al., 2005; Bordon, 
2013), where they help regulate the BBB and brain vasculature 
permeability (Armulik et al., 2010). It is the collective work of these 
cell types that together closely regulates the BBB functions. 
The BBB may appear to sound as a barrier that is either 
fixed or broken, however it is a permeable support that can be 
altered by modulators that lead to the barrier becoming leaky or 
permeable (Abbott, 2005), and weakening of the junctions. In cases 
when important molecules need to access the brain, this leaky 
property is vital, but if altered can lead to the permanent damage 
and huge infiltration of blood mononuclear cells, pathogens or 
viruses into the brain parenchyma, altering the highly protected 
homeostatic conditions within the brain.  
Entry of immune cells into the brain parenchyma, across the 
BBB occurs through two different steps, the physiological BBB and 
neuro-inflammatory BBB (Owens et al., 2008), and early reports 
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suggest that cytokine release can lead to activation of brain 
neuroglial and microglial cells, due to the opening of the BBB (Toro 
and Roman, 1978). Therefore in malaria infection, during the time 
window of CM induction the parasite is residing in iRBC at different 
maturity stages, from merozoite to schizont. The parasite is sitting 
in perfect position to be carried in the brain microvasculature and 
potentially exposed to unleash damage onto the brain parenchyma. 
Furthermore it has been shown that soluble factors from 
P.falciparum iRBC induce apoptosis in human brain vascular 
endothelial cells in vitro, suggesting that longtime exposure to such 
factors, could be associated to vascular; neuronal and tissue injury 
in malaria patients (Wilson et al., 2008). It is still a debatable topic 
as to whether the presence of the parasite causes damage directly, 
or whether it is the inflammatory responses acting on a normally 
quiescent brain parenchyma, that leads to the damaging cascade of 
events towards barrier breakage, coma and eventual death.  
 The breakage of the barrier during CM holds a general 
consensus at occurring during the final stages of CM induction, and 
is seen as the final unleashing of the inflammatory immune 
response upon the brain tissue. In some cases, if the gradual 
opening and increased permeability of the BBB is caught early 
enough in a malaria infection, symptoms of CM can be reversed 
and the patient saved from the induction of neurological downfall 
and death. One such study suggests that presence of the iRBC 
leads to constriction of the micro-vessels, leading to opening of the 
EC tight junctions, and that administration of anti-malaria drugs at 
the onset of human CM can abrogate this opening and cause 
survival of patients (Brewster et al., 1990; Nacer et al., 2012).  
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1.3 Innate immune response to Malaria 
 During malaria infection a host can develop partial immunity 
due to repeated exposure over a number of years, leading to a 
“pre-munition” state. Nevertheless this tends to wane in absence of 
exposure and upon moving away from endemic regions, clinical 
malaria immunity decays and is eventually lost (Autino et al., 2012). 
This ‘pre-munition’ is due to parasite strategies that evade sterile 
immunity, and build up of the host’s immune response, preventing 
clinical disease. This build up of immunity can be triggered by the 
shedding of protein parts from parasite polymorphic antigens during 
prolonged exposure in endemic regions (Autino et al., 2012). 
Therefore vital information is held within individual’s immune 
responses, and comparisons made within human populations living 
in malaria endemic areas against those in elimination areas, can 
provide clues in regard to the immune response properties of the 
malaria infection. 
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1.3.1 Cytokines 
 It has been reported numerous times, that it is the 
imbalance of pro and anti-inflammatory responses that causes the 
plethora of symptoms associated with severe malaria infections, 
and recent work has begun to show associations of cytokines and 
their receptors to malaria pathogenesis (Khor et al., 2007). 
Extensive work has shown the role of IFN-! related to CM 
development (de Kossodo and Grau, 1993; Villegas-Mendez et al., 
2012), where it was found that IFN-!-/- mice are protected from ECM 
induction upon PbA infection (Amani et al., 2000), with no 
leukocytes or parasites being found within the brain of these mice 
and absence of brain hemorrhages seen also (Villegas-Mendez et 
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al., 2012). In fact deletion of the IFN-!R, led also to protection from 
ECM in PbA infection in 129P2Sv/ev mice, (Belnoue et al., 2008), 
who showed further that leukocyte accumulation in the brain was 
hindered. This has led the way for showing the vital roles cytokines 
and Interferons play in ECM induction. This is further supported by 
(Parekh et al., 2006), who suggested that ECM development may 
be due to concentration of pro-inflammatory cytokines, such as IFN-
!, due to sequestered iRBC at the brain tissue site. Moreover 
increased levels of inflammatory cytokines involved in trafficking of 
T cells, such as MIP-1" and MIP-1# (Ochiel et al., 2005) and IP-10 
(Armah et al., 2007) have been shown in cases of CM patients. 
Finally IFN-! has been supported as being a key cytokine in 
providing a strong T helper 1 biased immune response, critical in 
the clearance of intra-cellular pathogens (Khor et al., 2007) and 
ECM has been referenced to as a classical IFN-! mediated disease 
(Villegas-Mendez et al., 2012). 
 
1.3.2 Toll like receptors  
 The response of type I IFN is first stimulated through the 
recognition of a pathogen by the germ-line encoded pattern 
recognition receptors (PRR), Toll like Receptors (TLR). PRRs 
recognize on each pathogen, pathogen associated molecular 
patterns (PAMPs), which initiates the first line of immune defense 
by the innate immune response (Janeway, 1989). 
TLR were the first type of PRR to be identified (Medzhitov et 
al., 1997) and so far ten TLRs have been indentified in humans 
(Takeda and Akira, 2004), and 12 identified in mice (Leulier and 
Lemaitre, 2008). TLRs are located either on the cell surface or 
intra-cellular vesicles (Kawai and Akira, 2011), with each TLR being 
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distinct in its recognition of PAMPs, for example TLR 4 recognizes 
Lipopolysaccharide (LPS); TLR 3, double-stranded RNA, and TLR 
9 binds DNA motifs (Akira and Takeda, 2004; Kawai and Akira, 
2011). Figure 1.3 illustrates the pathway of activation after a TLR 
has encountered a foreign microbe, such as a virus; bacteria or 
parasite. Upon recognition of their PAMPs each TLR recruits 
specific adaptor molecules that lead to an innate immune response, 
releasing inflammatory cytokines; chemokines and type I IFN. 
These responses further recruit macrophages; activate neutrophils 
and set in motion the stimulation of IFN genes (Dunne and O'Neill, 
2003; Kawai and Akira, 2010), together leading to eradication of the 
invading pathogen.  
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Figure 1.3 TLR9 pathway (Kawai and Akira, 2006). TLR7, 8, 9 
are located in the endosome of specific cells. After ligand 
attachment to the TLRs, this signals the MyD88-dependent 
pathway. In plasmacytoid DCs, Interferon regulatory factor (IRF) 7 
is constitutively expressed and forms a signaling complex with 
MyD88, Interleukin-1 receptor-associated kinase 1 (IRAK1) and 
IRAK4. In response to ligand stimulation, IRF7 is phosphorylated by 
IRAK1, dimerized and translocated to the nucleus. TNF-receptor 
associated factor (TRAF) 6-dependent ubiquitination is also needed 
for IRF7 activation, and together with NF-$B and Activator protein-1 
(AP-1), this regulates expression of Type I IFN.  
 
1.4 Type I IFN and IFNAR1 
 Analysis of Interferons has always been at the forefront of 
cytokine research (Taniguchi and Takaoka, 2002), with Interferons 
being first discovered by Alick Isaacs and Jean Lindemann in 1956, 
as cytokines released by virus infected cells (Isaacs and 
Lindenmann, 1957). Type I IFN was the first cytokine to be 
discovered, and was named so after its potential to “interfere” with 
viral effects (Isaacs and Lindenmann, 1987). Activation of type I IFN 
has been found to be anti-viral; anti-proliferative (Basler and 
Garcia-Sastre, 2002; Delhaye et al., 2006; Huys et al., 2009); arise 
anti-tumoral effects (Kawamoto et al., 2004), as well as govern 
overall immunomodulatory mechanisms as reviewed by (Gonzalez-
Navajas et al., 2012; Tompkins, 1999).  
 All nucleated mammalian cell types have the ability to 
produce type I IFN in response to viral infections (Ito et al., 2006), 
however it is a particular subset of plasmocytoid dendritic cells 
(pDC), that have been found to produce the most type I IFN (Cella 
et al., 1999), and with which have the ability to produce up to a 
hundred to a thousand times more type I IFN following viral 
infection (Siegal et al., 1999). 
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 There are 15 different subtypes of type I IFN, comprising 14 
IFN-" subtypes, and one IFN-# subtype, both bind and act through 
the type I IFN receptor – IFNAR (Stockinger and Decker, 2008; Uze 
et al., 2007). The IFNAR is a heterodimeric receptor composed by 
two membrane glycoproteins, IFNAR1 (") and IFNAR2 (#) 
(Takaoka et al., 2000; Wang and Fish, 2012). IFNAR1 exists as a 
single form, whilst IFNAR2 can exist as either a soluble (IFNAR2a), 
short (IFNAR2b), or long form (IFNAR2c) (Mogensen et al., 1999; 
Prejean and Colamonici, 2000). The IFNAR1 and IFNAR2 genes 
are located on chromosome 21q22.1, located in a cluster with 
genes that encode critical proteins for the immune response (Diop 
et al., 2006). Although the type I IFN receptors are expressed at low 
levels on the cell surface, from 102-103, they can efficiently transmit 
signals to the cell interior (Takaoka et al., 2000).  
 Figure 1.4 depicts the pathway leading to type I IFN 
stimulation. The pathway begins upon binding of either IFN "/B 
subunits to the IFNAR2 region of the heterodimer. However, 
IFNAR1 is considered the ‘signaling’ receptor, even though it does 
not bind directly to a IFN molecule, it is essential for the type I IFN 
signal transduction (Domanski and Colamonici, 1996). Each 
receptor subunit interacts specifically with a Janus activated kinase 
(JAK); IFNAR1 constitutively associates with tyrosine kinase 2 
(TYK2), and IFNAR2 with JAK1 (Darnell, 1998; Ihle, 1995). The 
initiating step in the type I IFN pathway is the activation of these 
JAKS by auto-phosphorylation following ligand (IFN"/#) attachment 
and dimerization of the receptor (Platanias, 2005; Silvennoinen et 
al., 1993). Activation of the JAKs then leads to activation of the 
classic JAK- signal transducer and activator of transcription (STAT) 
pathway, including STAT1, 2, 3 and 5 (Darnell, 1998), which form 
either homo or hetero-dimers, such as STAT1-STAT3, that then 
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translocate to the cell nucleus where they bind to specific sites in 
the promoter region of the IFN stimulated genes (ISGs) (Darnell, 
1997; Stark et al., 1998).  
A unique element in the type I IFN pathway remains the 
formation of the complex ISG factor 3 (ISGF3), formed by STAT1, 
STAT2 and IFN regulatory factor (IRF) 9. This collective complex, 
ISGF3, binds to specific IFN-stimulated response elements (ISREs) 
in the promoter regions of the ISGs leading to the transcription of 
the type I IFN genes (Platanias, 2005). It is this original model of 
the JAK-STAT pathway discovered in the 1990s that remains 
principle in the type I IFN immune response. There are a number of 
varying pathways that can be stimulated alongside the JAK-STAT 
pathway, which could explain the pleiotrophic roles that Type I IFN 
plays in a host immune response (Platanias, 2005). 
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Figure 1.4. Interferon Type I pathway. (Prinz and Kalinke, 2010), 
All types of Type I IFN act through the single cell surface receptor 
composed of the "-chain IFNAR1 and #-chain IFNAR2. The two 
chains are linked to tyrosine kinase TyK2 and Jak1.  Upon binding 
of either IFN-"/#, to the IFNAR1+2 chains, this induces the 
transcription factor, signal ransducers and activators of transcription 
(STAT) 2 and IFNAR2 binding. STAT1 is then recruited to STAT2 
and upon tyrosine phosphorylation is released and associated with 
Interferon regulatory factor (IRF) 9. Together with p48, this forms a 
heterodimeric IFN stimulated gene factor (ISGF) 3 complex that 
translocates to the nucleus and binds to IFN-stimulated regulatory 
elements (ISRE). At the same time STAT1 homodimers (AAF) and 
other STAT complexes, STAT3, STAT5, STAT1/STAT3, 
STAT5/CrKL heterodimers also form. AAF and STAT5/CrKL 
translocate to the nucleus and bind to IFN-! activated sequences 
(GAS). (Adapted and re-printed with permission).  
 
 
 Interferons are also found to be highly species specific 
(Erdmann et al., 2011), which potentially explains the vast array of 
responses induced by Interferons during immune responses in the 
body, and with currently over 300 ISGs identified (de Veer et al., 
2001), this supports the monumental role type I IFNs play within the 
innate immune response.  
Innate immune response to malaria infection is evidenced 
by the first TLR associated with malaria parasite recognition being 
TLR9 (Pichyangkul et al., 2004). It was discovered that extracts 
from schizont stage parasites during P.falciparum infection may 
contain the ligand detected by TLR9 which stimulates the innate 
immune response. Further, the recent work of (Sharma et al., 2011) 
has extensively explored the mechanism by which parasites are 
detected within the innate immune system. During the blood stage 
of infection, parasites digest haemoglobin, producing hemozoin, an 
inert crystal. It is this crystal hemozoin, that the authors report 
carries a Plasmodium DNA motif (identified as ATTTTTAC), that is 
the trigger of TLR9 and innate immune recognition. The ingestion of 
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the hemozoin into the endosomal compartment, then allows CpG 
motifs on the crystalline surface to be recognized. Further 
destabilization of the phagosome leads to the release of material 
into the cell cytosol, containing the AT-rich stem loop DNA motif, 
and triggering innate immune responses. The response through 
TLR9 signaling leads to up-regulation of IFN-I stimulatory genes, 
(Sharma et al., 2011), and supports the involvement of type I IFN in 
malaria innate immune responses.  
Recent publications have also arisen studying the role of type I 
IFNs during CM. Strong evidence supports their multi-functional 
role in malaria due to the large increase of IFN-stimulated genes 
(ISGs) and essential gene components of the IFN signaling 
pathway, such as signal transducers and the IRF family, being up-
regulated during PbA infection (Miu et al., 2008). Further, both type 
I IFN and TLR have been hypothesized as bridging the adaptive 
and innate immune response (Biron, 2001; Khor et al., 2007; Le 
Bon and Tough, 2002).  
 
1.5 Adaptive immune response to malaria 
1.5.1 T cells 
 The role of T cells has been paramount in CM pathogenesis 
research. It has been corroborated that CD4+ T cells intervene 
during the induction stage of ECM, whilst CD8+ T cells play their 
prominent role in the effector phase of the immune response in the 
brain tissue. This has been shown extensively in ECM research, 
begun by (Grau et al., 1986), who gave evidence of the necessity of 
T cells in mounting a CM response, and supported the early 
findings of the role of T cells in CM by (Finley et al., 1982).  
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T cell responses that help drive susceptibility versus 
resistance to parasite infection have been linked with CD4+ T cell 
involvement (Mosmann and Coffman, 1989). However, early 
research findings contrast in their results, naming CD4+ T cells 
responsible for ECM induction (Grau et al., 1986); opposed to 
solely CD8+ T cells (Waki et al., 1992); opposed to both CD4+ and 
CD8+ T cells (Hermsen et al., 1997). Discrepancies they conclude, 
could be due to differing mouse strains or P.berghei strains of 
infection, however together these early studies clearly showcased 
the essential involvement of T cells within CM development.  
 In support, complete lymphocyte ablation in the mouse 
model of Rag2-/- (Nitcheu et al., 2003) and Rag1-/- (Amante et al., 
2010) results in 100% protection from ECM development, as well 
as individual depletion of CD4+ T cells, via MHC-II knockout (A 0/0) 
and CD8+ T cells, via MHC-I knockout mice ("2m 0/0) also result in 
protection from ECM, (Yanez et al., 1996). However this suggests a 
need for deciphering between the exact role of T cells as opposed 
to the major histocompatibility complex (MHC) involvement in ECM 
induction.  
 Abundant literature is focused on the role of CD8+ T cell in 
ECM, including, CD8 knockout mice; antibodies against CD8+ T 
cells and depletion of CD8+ T cells (Belnoue et al., 2002; Hermsen 
et al., 1997; Yanez et al., 1996). Together this work showed that the 
cytotoxic function of CD8+ T cells (CTL) via perforin and Granzyme 
B (Haque et al., 2011b; Nitcheu et al., 2003), is instrumental to their 
pathogenic role as effector T cells in CM development. However 
these works have lacked in exploring the ultimate trigger for the 
cytotoxic role of the activated CD8+ T cell in CM. 
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1.5.2 Effector CD8
+
 T cells 
 Cytotoxic T cells (CTL) are a subset of CD8+ T lymphocytes, 
whose role once activated, is to kill infected, damaged or 
dysfunctional cells, and are critical in maintaining proper functioning 
of the immune system (Jerome et al., 2003). A review by (Aidoo 
and Udhayakumar, 2000) presented how CTL T cells are seen as a 
potential target for drug vaccine development and suggest a natural 
CTL induction might be influenced by parasite variants, host genes 
and transmission patterns (Aidoo and Udhayakumar, 2000).   
CTLs have a specialized mechanism to induce apoptosis of 
infected host cell, triggered by activation of the T cell receptor 
(TCR), upon recognition of a specific antigen (Ag), that is presented 
in the context of MHC class I, on the surface of a target cell 
(Jerome et al., 2003). Apoptosis is induced in this target cell, which 
requires direct effector-target cell contact (Trapani and Smyth, 
2002) and induces release of Granzyme B (GrB) and Perforin into 
the target cell, triggering apoptosis via the caspase cascade (Smyth 
and Trapani, 1995). GrB is a serine protease that requires perforin 
to form channels for its entry into the target cell and released from 
the endosome into the target cell cytoplasm where it cleaves 
caspases, activating the caspase casade of apoptosis (Shi et al., 
1997). GrB can induce rapid apoptosis within four hours in most cell 
types (Heusel et al., 1994), and has also been shown to work 
independent of the caspase cascade (Sarin et al., 1997). 
GrB and perforin have been shown to be instrumental to 
ECM development (Haque et al., 2011b; Nitcheu et al., 2003), and 
in the context of malaria infection it appears both knockout mice are 
protected from ECM development, independent of the other 
molecule. Moreover GrB mRNA has also been shown to be 
!%)!
increased in response to murine malaria infections (Miu et al., 
2008), most strongly during PbA infections. 
A secondary apoptosis pathway is also used by CTL T cells 
in cell target directed killing, the Fas/FasL pathway (Van Parijs and 
Abbas, 1996), however mice deficient for Fas (gld-/-), or FasL (Lpr-/-
), are still susceptible to ECM development (Potter et al., 2006), 
therefore concluding that apoptosis via cytoplasmic granules is the 
pathway used in malaria infections. 
 
1.5.3 Chemokines 
 Chemokines have also gradually showed their vital roles in 
mediating both the type I IFN and CD8+ T cell roles within CM 
development. Both ECM resistant and susceptible mouse strains 
have shown up regulation of chemokine genes in response to PbA 
infection, in the brain; liver and spleen, representing the large part 
chemokines play in the innate immune response (Hanum et al., 
2003). 
Elegant work by (Campanella et al., 2008), showed the 
essential need of CXCR3 receptor expression for migration of CD8+ 
T cells to the brain, through the use of CXCR3-/- mice, and the 
ability to induce ECM by adoptive wildtype CD8+ T cell transfers to 
CXCR3-/- mice. In keeping with this response, depletion of natural 
killer (NK) cells from C57BL/6 mice, therefore down-regulation of 
CXCR3, led to protection from ECM also (Hansen et al., 2007). 
Furthermore down regulation of inflammatory response via 
neutralization of IP-10, the ligand of CXCR3, and IP-10-/- mice, 
protected development of ECM in PbA lethal infections (Nie et al., 
2009). This led to increased retention of parasites within the spleen, 
controlling parasite burden throughout and decreased T cell 
! %*!
mediated trafficking to the brain, resulting in protection from ECM. 
Evidence thereby classifies chemokines as essential 
supporters in the vital effects T cells incur within the brain tissue 
leading to development of ECM. However, it still remains to be seen 
whether susceptibility to CM is correlated with a particular pattern of 
cytokine production (de Kossodo and Grau, 1993). 
 
 In conclusion Figure 1.5 depicts the current understanding 
of the ECM mouse model and the key players mediating the 
development and pathogenesis of this disease state. This thesis 
aims now forth to discuss in detail the role of type I Interferon, 
mediated through the IFNAR1, during CM development.  
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Figure 1.5 Experimental Cerebral malaria pathogenesis. 
(Schofield and Grau, 2005). pRBC adhere to receptors expressed 
by brain microvascular EC. When merozoites are released from 
pRBC ~4 hr later, parasite glycosylphosphatidylinositol (GPI), 
functions as a pattern-associated molecular pattern and toxin, 
stimulating the host inflammatory response. A local response is 
induced, involving activation of endothelium and production of 
cytokines and chemokines. Following the next 24hr this cycle is 
exacerbated. Natural killer T cells (NKT) cells, recruit CD4+ T cells. 
Chemokines further recruit monocyte and activate neutrophils. 
Monocytes develop into macrophages, enhanced by IFN-!, 
releasing further chemokines, amplifying this cycle. Platelets can be 
further arrested in microvessels, along with macrophages leading to 
hightened pro-inflammatory effects. Finally damage to endothelium 
is caused, leading to possible perivascular haemorrhage, axonal 
injury and alterations of the brain parenchyma. (Adapted and re-
printed with authors permission).  
1.6 Aims of this thesis 
Cerebral Malaria is the result of an overwhelming immune 
response to infection by Plasmodium falciparum parasite. Current 
research is trying to understand the exact mechanisms that lead to 
CM development, where there might be potential aims for 
therapeutic intervention.  
The clinical diagnosis of CM is difficult in both the human 
and mouse models (de Souza et al., 2010), thus making it 
particularly hard to target onset of CM disease. Research from 
human cases in endemic areas of malaria infection provides clues 
as to how host immunity is built and how the immune system fights 
against infection from the Plasmodium parasite. Type I interferon 
has been shown to govern the innate immune response (Delhaye et 
al., 2006; Gonzalez-Navajas et al., 2012), and evidence is mounting 
for its role as a potential candidate for CM prevention strategies 
(Aucan et al., 2003; Driss et al., 2011).  
! &"!
In the case of ECM development, CD8+ T cells are 
instrumental in this fight (Belnoue et al., 2008; Hermsen et al., 
1997), yet their intrinsic triggering mechanism to unleash their 
pathological role still remains unsolved.  
The overall goal of this thesis work was to evaluate the 
resistance of Ifnar1-/- mice to ECM induction, and uncover the 
mechanism by which IFNAR1 is important during a malaria 
infection. We aimed specifically to assess whether a particular 
immune cell type governs the type I IFN response during ECM 
development, and successfully showed this through the design of a 
novel cell transfer protocol. We aimed further to characterize the 
activation status and activity of immune cells that abrogated the 
CD8+ T cell profile, and to understand the involvement of type I IFN 
upon CD8+ T cell pathogenic function, during PbA infection. 
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Chapter 2  
Development of Pre-sensitization,  
Cell transfer Protocol 
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2.1 Author contribution 
The protocol design and transfer experiments were 
conceived by myself and my supervisor Carlos Penha-Gonçalves. 
All experiments were carried out by me.  
This pre-sensitization protocol has been accepted for publication in 
the Methods in Malaria Research Handbook: 
(http://www.mr4.org/Publications/MethodsinMalariaResearch.aspx) 
and will be published in the up and coming edition, (Appendix One). !
2.2 Summary  
 Response to induction of Experimental Cerebral Malaria 
(ECM) in mouse strains can be classified as susceptible vs 
resistant. Current techniques exist for assessing mortality occurring 
by ECM, such as symptom onset, breakage of the blood brain 
barrier and presence of sequestered parasite in the brain tissue. 
However there is no reliable method to assess the role of individual 
cell types in the immunological responses underlying CM 
development.  
This chapter describes the development of a novel pre-
sensitization protocol we devised as a method to test potential 
induction and protection from ECM via select cell transfer 
techniques in ECM resistant mouse strains. We used this protocol 
to show that presence of IFNAR1 in CD8+ cells is sufficient to 
restore ECM susceptibility in previously resistant Ifnar1-/- mice. Our 
design of an irradiation step within this protocol further uncovered 
the necessity of priming spleen CD8+ cells for ECM induction. We 
suggest that this protocol be used for future experiments in 
denoting key cellular players of ECM development.  
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2.3 Introduction 
 The experimental field of CM has no consistent method for 
assessing individual cell type ability at induction of Experimental 
cerebral malaria (ECM) in mice models. Much work has been 
published for individual knockout mouse strains reporting that loss 
of activity such as CD8-/-, CD4-/- (Claser et al., 2011) and or 
increased activity of specific cells such as dendritic cells (DC) 
(Tamura et al., 2011) is linked to ECM susceptibility or resistance. 
Individual focus on cellular expression of the chemokine receptor 
CXCR3; pro-inflammatory molecule TNF-" (Morrell et al., 2011); 
loss of function of GrB (Haque et al., 2011); as well as HO-1 
protective capacities (Pamplona et al., 2007), have also led to ECM 
resistance. Therefore a specific technique for determining cellular 
involvement in pathogenesis is greatly needed to help test and 
define the key players in ECM development and prevention. 
Work by (Nitcheu et al., 2003) has shown that ECM was 
induced in ECM resistant Rag2-/- mice through a transfer technique 
using total splenocytes from PbA infected C57BL/6 mice. However, 
in our hands we were unable to replicate these procedures without 
co-transfer of PbA infection to recipient mice. We developed 
therefore a novel cell transfer technique that could show how a 
particular cell type presence could lead to susceptibility vs 
resistance in select strains of mice.  
We studied total spleen and purified CD8+ cell transfers 
between C57BL/6 (ECM susceptible) and Ifnar1-/-, Rag2-/- and CD8-
/- (ECM resistant) mouse strains. Through development of this 
transfer method we uncovered the necessity of a priming response, 
brought about via irradiating infected red blood cells (iRBC) taken 
from the spleen of donor mouse. This irradiation step proved 
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essential for inducing ECM in a previously resistant Ifnar1-/- mouse 
model.  
 We further established that exposing cell donor mice to 
infection before transfer of cells to recipient mice was instrumental 
for ECM induction, but established this protocol as a pre-
sensitization not an immunization protocol. Although we could not 
produce sufficient ECM induction in Rag2-/- or CD8-/- mice, we show 
here preliminary results that our technique warrants further study in 
these mouse strains.  
Together this work has uncovered the importance of primed 
CD8+ cells in ECM development. Through this discovery we have 
established a new tool for ECM research which we believe will be 
essential for future ECM studies in the mouse model.  
2.4 Materials and Methods 
2.4.1 Animals 
 The protocol can use different combinations of males, 8-12 
weeks old as cell donors and recipients. We performed criss-
crossed transfer experiments using  C57BL/6 mice or knockout 
mice backcrossed into the C57BL/6 background. iRBC donors were 
H2-compatible with the recipients. All procedures were in 
accordance with national regulations on animal experimentation 
and welfare as approved by the Instituto Gulbenkian de Ciência 
Ethics committee and the animal welfare national authority.  
2.4.2 Parasite, infection and ECM disease 
assessment 
All infections used 1 % 106 P.berghei ANKA-GFP parasitized 
iRBC (Franke-Fayard et al., 2004) given via intra-peritoneal (i.p) 
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injection. Frozen iRBC stocks were expanded in C57BL/6 mice 
prior to infection. Parasitemia was determined as the % of GFP+ red 
blood cells, using flow cytometry analysis (FacScan Cell Analyser, 
Becton Dickinson, New Jersey) and non-infected RBCs as negative 
control. ECM development was monitored from day 5 post-infection 
(PI) as including; head deviations, paralysis, ataxia and convulsions 
(Pamplona et al., 2007). ECM susceptible mice developed 
symptoms at days 6-7 post-infection and died within 4-5 hours. 
Mice resistant to ECM died around days 22-25 from anemia and 
hyperparasitemia without displaying neurological symptoms. 
2.4.3 Pre-Sensitization protocol  
(Please see Figure 2.4 also as guidance). 
For infected blood donor mice; blood was collected by 
mandibular vein puncture into an eppendorf containing 10 µl of 
Heparin (Heparina Leo, Leo Pharmaceutical products) from infected 
mouse at day 6 post-infection, upon display of ECM symptoms and 
when parasitemia was around 30%. Parasitemia was measured to 
calculate injection of 4 % 106 iRBC into cell donor mice. Collected 
blood was then placed on ice in a 50 ml falcon tube and irradiated 
at 20 k Rad (GAMMACELL 2000, MØLSGAARD Medical 
Denmark). Irradiated iRBC were then re-suspended in PBS and 
injected i.p into cell donor mice. At day 6 post irradiated-iRBC 
injection, cell donor mice were sacrificed and purified spleen cell 
populations were injected into recipient mice; recipient mice were 
left either non-infected (NI) or infected 1 % 106 PbA i.p one hour 
after transfer. Parasitemia and ECM development were monitored 
from day 5 post-infection. For control non-infected blood donor 
mice; mice were bled and an equivalent volume of non-infected 
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RBC were irradiated and diluted in PBS in the same manner as 
above.   
2.4.4 Spleen cell preparations  
Single cell suspensions were prepared from spleens of cell 
donor mice. For total spleen cell transfers; cells were washed 2 % in 
PBS, counted in a hemocytometer, re-suspended in PBS and 
injected either 3 or 5 %106/ 100 µl into recipient mice.  
For spleen CD8+ cell transfers; cells were washed 2 % in 
PBS 2%FCS and incubated with anti-mouse CD8-alexa647 
antibody (clone YTS169, in house production), for 30 min on ice. 
Stained cells were washed in PBS 2%FCS and sorted (FacsAria 
Multicolour Cell Sorter, Becton Dickinson, New Jersey) by 
combining lymphocyte morphological gating and relevant antibody 
labels. For CD8+ transfers; cells were collected as purified CD8+ 
cells and CD8- (depleted) groups of cells. Purified cell populations 
were washed in PBS and counted. Cells were injected 
intravenously (i.v) either 3 or 5 % 106/ 100 µl into recipient mice. 
Respective groups of recipient mice were then infected 1 % 106 
iRBC/ 100 µl PbA one hour after cell transfer (as per standard 
infection, described previously). Mice were monitored for 
parasitemia and ECM development from day 5 post-infection. 
 
2.5 Results 
2.5.1 Total splenocyte cell transfers to Rag2-/- mice 
 We first investigated the process of transferring cell types 
between groups of knockout mice. Using this method we 
hypothesized that selected cell transfers from C57BL/6 and Ifnar1-/- 
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mice into various mice strains, could lead to ECM induction vs ECM 
prevention.  
We set to replicate the results seen in the paper (Nitcheu et 
al., 2003), where it was shown transfer of C57BL/6 total 
splenocytes to Rag2-/- mice caused 100% death from ECM, by day 
8 post-infection. However we found we were unable to replicate 
these results. Figure 2.1 shows our initial findings, whereby transfer 
of total splenocytes from infected C57BL/6 mice vs Ifnar1-/- mice to 
Rag2-/- mice, led to a steady increase in parasitemia levels, but saw 
no significant differences between recipient Rag2-/- mice or either 
compared against control Rag2-/- mice that received infection only, 
and no cell transfer (Figure 2.1 A). Roughly all recipient mice died 
around day 30 post-infection, with control mice dying around day 40 
post-infection (Figure 2.1 B). Recipient mice were kept for two 
weeks post transfer to allow for re-constitution of immune 
compartments.  
This initial experiment was further repeated with recipient 
mice infected one hour post cell transfer (figure 2.1 C, D). Again we 
noted no significant difference between parasite loads in both 
groups of recipient mice (Figure 2.1 C), although parasite levels do 
not appear to reach as high as in Figure 2.1 A. We did find 25% of 
Rag2-/- mice that received total splenocytes from C57BL/6 mice, 
died within the time window for ECM (shadowed box in Figure 2.1 
D). However, this did not match the previously reported 100% 
incidence, therefore we concluded that spleen cell populations, in 
our hands, proved not fully competent at inducing ECM in 
previously resistant Rag2-/- mice.  
!('!
 
Figure 2.1. Rag2-/- mice partially resist to develop ECM upon 
transfer of C57BL/6 total splenocytes. Parasitemia and survival 
curves of Rag2-/- mice that received 5 % 106 total splenocytes from 
either C57BL/6 mice (open squares), or Ifnar1-/- mice (open circles), 
as compared to Rag2-/- mice that were infected only as a control 
(closed squares). Recipient mice were either infected 1 % 106 PbA 
(i.p) two weeks post splenocyte cell transfer (A, B), or one hour 
after cell transfer (C, D). 
 
 
We continued our efforts to obtain a susceptible ECM 
phenotype in Rag2-/-, mice, this time using sorted T cell transfers 
from lymph nodes of C57BL/6 vs Ifnar1-/- mice, and assessing 
whether these cells were sufficient for the ECM triggering in Rag2-/- 
mice. We hypothesized that transfer of naïve T cells from lymph 
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nodes, plus four weeks of reconstitution in Rag2-/- mice, might 
establish a larger pool of T cells within the recipient spleen and lead 
to an increased ability at triggering ECM in Rag2-/- mice. We found 
both groups of recipient mice developed parasitemia alike the 
previous total splenocyte transfers, with a slightly higher 
parasitemia being seen in recipient mice that received purified T 
cells from C57BL/6 mice compared to Ifnar1-/- transfer (Figure 2.2 
A). But in contrast to our previous efforts, we found a 25% 
incidence of ECM in Rag2-/- mice that received C57BL/6 purified 
lymph node T cells. This was in comparison to a 40% incidence of 
ECM in mice that received Ifnar1-/- purified lymph node T cells 
(Figure 2.2 B). However as these results were not significantly 
different, and we were unable to reproduce a near 100% ECM 
incidence, we deemed this method of inducing Rag2-/- ECM 
insufficient to accomplish our goals. 
  
 
Figure 2.2. Purified lymph node T cells partially abrogate ECM 
resistance in Rag2-/- mice. Parasitemia (A), and survival curve (B) 
of Rag2-/- mice that received total T cells purified from lymph nodes 
of either C57BL/6 mice (open squares) or Ifnar1-/- mice (open 
circles).  
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2.5.2 ECM susceptibility in previously resistant Ifnar1-
/- mice 
 We next attempted the possibility at restoring susceptibility 
to ECM in resistant Ifnar1-/- mice. Total splenocytes were 
transferred from previously infected C57BL/6 donor mice to Ifnar1-/- 
mice (as detailed above). Recipient mice were then divided into two 
groups, one group was infected 1 % 106 PbA one hour after 
infection; and the other group was left untreated (no infection). We 
found to our surprise that we were able to induce ECM in the 
previously resistant Ifnar1-/- mouse strain (Figure 2.3 B). However 
what was obscure is we found ECM incidence in both groups of 
recipient mice, even mice that were not infected post cell transfer. 
This was confirmed with both groups of mice developing 
parasitemia, albeit the untreated group from a lower starting 
percentage (Figure 2.3 A). In fact when we repeated this 
experiment by performing purified CD8+ cell transfers from infected 
C57BL/6 donor mice to Ifnar1-/- recipients, we found the same 
incidence of ECM (Figure 2.3 D), and both recipients (post infected 
and untreated) developed parasitemia (Figure 2.3 C). 
! (*!
 
 
Figure 2.3 Ifnar1-/- mice succumb to ECM upon transfer of total 
splenocytes from previously infected C57BL/6 mice. 
Parasitemia and survival curves of Ifnar1-/- recipient mice that 
received either total splenocytes (A, B) or purified CD8+ cells (C, D) 
from C57BL/6 mice. Recipient mice were either infected one hour 
post cell transfer (open squares or circles), or left untreated (closed 
squares or circles). Statistics, parasitemia; unpaired t-test, ***P 
&0.001. 
 
 
It seemed likely therefore that the ECM susceptibility we 
were recording was from the infected red blood cells (iRBC) being 
passed from the infected C57BL/6 donor mice. Therefore we aimed 
to establish a method of eliminating these invading parasites and to 
allow questioning whether Ifnar1-/- mice were susceptible to ECM 
due to the later infection after cell transfer. 
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2.5.3 Irradiated infected red blood cell passage 
 We began to explore the possibilities of irradiating parasites 
in the inoculum given to cell donor mice. We hypothesized that the 
process of irradiation would damage the DNA of the parasite 
preventing re-invasion of healthy RBCs within the cell donor mouse. 
With reference to (de Souza and Playfair, 1983), we 
established that a previously infected mouse at 30% parasitemia 
could be used to obtain blood for passage into a new host, and 
would lead to host immune responses. The work of (Ocana-
Morgner et al., 2003) was also referenced in establishing irradiation 
amount for cell populations. We set up a model using a day 6 post-
infection C57BL/6 mouse, showing symptoms of ECM and 
parasitemia of 30%. Blood was taken, irradiated at 20 K rad, and 
re-injected 1 % 106 iRBC, into mice to be used as cell donors. The 
schematic of this protocol is shown in Figure 2.4.  
 
 
 
Figure 2.4. Schematic representation of pre-sensitization 
protocol. iRBCs are taken from an initial blood donor, irradiated 
and passed to cell donor mice. Six days post-injection, selected cell 
types are sorted from cell donor mice, and injected into Ifnar1-/- 
recipient groups. Recipients were then either, infected one-hour 
post transfer or left untreated. 
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To test the response of passage of irradiated iRBC, 
C57BL/6 mice received irradiated iRBC and were followed for 
development of parasitemia or ECM development. We found after 
two months observation, no incidence of parasitemia or ECM.  
Furthermore a second control was performed in which C57BL/6 
mice received irradiated iRBC and were then infected 1 % 106 PbA, 
seven days after. We found all mice succumbed to ECM as per 
standard infection (Figure 2.5 B). We performed the same control 
experiment with Ifnar1-/- mice that received irradiated iRBC and 
seven days after were infected 1 % 106 PbA. All mice were resistant 
to ECM development, as compared to Ifnar1-/- mice that received 
infection only (Figure 2.5 B). We noted also Ifnar1-/- mice that 
received irradiated iRBC displayed lower parasitemia as compared 
to control Ifnar1-/- mice (Figure 2.5 A).  
 
 
 
Figure 2.5. Ifnar1-/-mice show reduced parasitemia upon 
receiving irradiated iRBC and later infection. Ifnar1-/- mice 
received 1 % 106 irradiated iRBC (i.p) from donor C57BL/6 (wt) 
mice, and 6 days later 1 % 106 PbA standard infection (i.p). 
Statistics, parasitemia; unpaired t-test, *P &0.05, survival curves; 
Log-rank Test, open squares against open circles). 
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Overall we concluded that that this protocol was not an 
immunization protocol, thus meaning that exposure to irradiated 
iRBC from previously infected C57BL/6 mice did not induce in 
recipient C57BL/6 mice, a protective response from a later standard 
infection and furthermore did not alter the profile of ECM resistance 
in Ifnar1-/- mice. 
 
2.5.4 Cell transfer experiments with CD8-/- mice 
 We hypothesized therefore that after successful induction of 
ECM in Ifnar1-/- mice, transfer of purified CD8+ cells from C57BL/6 
mice could induce ECM susceptibility in previously resistant CD8-/- 
mice. The hypothesis we tested was that transfer of IFNAR1+ CD8+ 
T cells from C57BL/6 mice would induce ECM in CD8-/- mice, 
whereas transfer of IFNAR1- CD8+ T cells from Ifnar1-/- mice would 
maintain ECM resistance in CD8-/- mice.   
We tested our now established protocol but were unable to 
obtain any conclusive results for ECM incidence in CD8-/- mice. We 
varied further our protocol set-up in the assumption that cell number 
and reconstitution time also factored in to ECM susceptibility. We 
altered, increasing the number of CD8+ T cells transferred, up to 5 % 
106 (Figure 2.6, open diamonds); increasing the time between cell 
transfer and infection of the CD8-/- mice, one hour and 24 hour post 
cell transfer (Figure 2.6 open squares vs open circles). We found a 
fraction of recipients developed ECM when transferring 5 % 106 
IFNAR1+ CD8+ cells (open diamonds), suggesting that the 
irradiation protocol is able to induce CD8+ cells and evoke ECM in a 
genetically resistance mouse. These early results implied these 
experiments warrant further exploration. 
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Figure 2.6. Partial abrogation of ECM resistance in CD8-/- mice 
upon CD8+ cell transfer. Survival curves of CD8-/- mice that 
received CD8+ splenic cells of  previously exposed C57BL/6 mice 
either: 3 % 106 cells and injected with PbA one hour after cell 
transfer (open squares); 3 % 106 cells and infected 24 hours after 
cells transfer (open circles); 5 % 106 cells and infected 24 hours 
after cell transfer (open diamonds). CD8-/- mice untreated and 
infected with PbA only were used as controls (closed squares). (i)wt 
indicates C57BL/6 mice that were exposed to irradiated iRBC. Time 
window for ECM susceptibility shadowed. 
 
 
2.6 Discussion 
These results show the development of a novel cell transfer 
protocol which highlights the introduction of irradiated iRBCs that 
led to ‘priming’ of splenic immune cells. Previous work has found 
that irradiating parasite sporozoites does not limit parasite antigen 
(Ag) synthesis but causes parasites to break open and shed their 
!)%!
Ag into surrounding cytoplasm of the infected cell (Suhrbier et al., 
1990). We could suggest therefore that the irradiation step in our 
protocol halts parasite re-invasion whilst keeping parasite Ag 
available to activate immune system cells within the spleen. This 
step we prove does not grant immunity to susceptible mouse 
strains in a later infection, but instead primes potentially CD8+ T 
cells for a secondary Ag encounter upon later infection time points.  
Priming of CD8+ T cells can result in the induction of a 
cytolytic (CTL) profile from recognition of a pre-existing Ag 
(Kohlmeier et al., 2010), thus allowing T cells a faster response 
upon Ag re-encounter. Inflammatory responses during priming can 
also act upon CD8+ T cell responses (Badovinac et al., 2005; Joshi 
and Kaech, 2008). Extensive work by (Curtsinger et al., 2005) has 
shown that CD8+ T cells need three signals to become fully 
activated: an Ag; co-stimulation and a third signal via a type I 
interferon. Furthermore the effects of type I IFN upon T cells is 
dependent on the continued exposure of T cells to type I IFN 
(Stewart, 2003), Therefore our work supports the notion that 
priming is required in CD8+ T cells, to induce ECM onset. 
It is difficult to explain however why we could not induce 
high incidence of ECM in Rag2-/- mice. Early work by (Grau et al., 
1986) made use of an irradiation protocol, producing bone marrow 
transgenic CBA background mice, first irradiating to allow graft 
acceptance and then transferring selective cell populations. It could 
be suggested therefore that first establishing T cell populations 
within a resistant mouse strain, (as we tried for Rag2-/- mice), and 
then priming these mice with irradiated iRBC, might trigger a 
priming response in a now present CD8+ population and lead to 
ECM triggering. It was interesting also that similar partial induction 
of 50% incidence of ECM was observed by other authors in 
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recipient Rag1-/- mice (Lundie et al., 2008). They could not explain 
the reasoning behind only 3/6 experiments working successfully, 
which corroborates with our data. The fact they also induced a 
priming step for spleen cells, points again to this as a key part in 
successfully inducing ECM in previously resistant mice strains.  
We were able to induce low incidence of ECM in both Rag2-
/- and CD8-/- mouse strains which warrants future work using higher 
number of transferred CD8+ cells, combined with initiating priming 
in these mice, suggests that our protocol could be further adapted 
for testing ECM resistant mouse strains. Furthermore work by (Prlic 
et al., 2006) suggests that CD8+ T cells need less than seven hours 
to receive all their necessary signals to become a full effector cell, 
and that 48 hours would be optimal for CD8+ T cell proliferation and 
survival. The same group also commented that exposure time to Ag 
dictated the accumulation of CD8+ T cells in the spleen.  Therefore 
our future efforts could aim at introducing a larger number of 
parasite Ag and boost the priming challenge in Rag2-/- and CD8-/- 
mice, prior to later infections with live parasite. 
 It is important to conclude that the role of CD8+ T cells in 
ECM development is not completely resolved. It has been shown 
through wildtype CD8+ T cell transfers, specific components of 
CD8+ T cells that contribute to ECM induction (Campanella et al., 
2008; Miu et al., 2008; Yanez et al., 1996) but there still remains no 
consistent method to perform these cell transfers. In fact the vast 
majority of reports collectively fail to show non-infected control 
CD8+ cell transfers, thereby exposing their work as potentially 
inducing ECM through passage of iRBC to their recipient mice. We 
believe our novel protocol fits well in the place of a uniformed 
method for specified cell transfers, and would be instrumental for 
future cell transfer experiments aiming at inducing ECM. With future 
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work dedicated to solving the induction of Rag2-/- and CD8-/- mice 
transfers, a mouse strain that has never actually been induced to 
ECM susceptibility, would be relevant in supporting our protocol. 
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Chapter 3  
Article I 
IFNAR1 Controls Progression to Cerebral Malaria in 
Children and CD8+ T cell Brain Pathology in Plasmodium 
berghei-Infected Mice. 
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supervisor Carlos Penha-Gonçalves and myself. All mouse 
experiments and analyses were performed by me. 
Maria Rosário Sambo orchestrated human sample collections. 
Maria Rosário Sambo, Maria Jesus Trovoada, Lígia Antunes 
Gonçalves performed human sample processing and genotyping. 
Maria Rosário Sambo and Madalena Martins conducted the human 
genetic analysis. Manuscript was written by myself and Carlos 
Penha-Gonçalves, with contributions from Madalena Martins. 
António Coutinho and Carlos Penha-Gonçalves conceived the 
original human study design. 
3.2 Summary  
Development of cerebral malaria (CM), a severe and fatal form 
of clinical Plasmodium falciparum infection, results from a 
damaging cascade of vascular, inflammatory and immunological 
host responses that leads to brain injury. Progression to CM can be 
modified by host genetic factors. Our case-control study in Angolan 
children aimed at highlighting the role of Interferon (alpha, beta) 
Receptor 1 (IFNAR1) in progression to CM. We report here robust 
association between IFNAR1 and CM protection, and detailed 
mouse studies showing analogous protection from Experimental 
CM in Ifnar1-/- mice infected with Plasmodium berghei ANKA-GFP. 
We developed a novel cell transfer protocol that enables spleen cell 
priming in absence of disease. This led to discover that IFNAR1 
expression in CD8+ T cells is crucial, and can abrogate resistance 
to ECM in Ifnar1-/- mice. Splenic CD8+ T cells from Ifnar1-/- mice are 
functionally activated upon infection, yet are unable to mediate 
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ECM development within the brain tissue. Our findings prove that 
IFNAR1 signaling unleashes CD8+ T cell effector capacity-vital for 
CM-and raises the hypothesis that the cohesive role of IFNAR1 in 
both human and mouse CM, operates through CD8+ T cell 
triggering.  
3.3 Introduction 
Cerebral malaria (CM) is a severe and often fatal, complicated 
form of Plasmodium falciparum malaria, affecting mostly children in 
endemic regions (1-3). While adhesion and sequestration of 
infected red blood cells (iRBCs) in brain microvasculature leads to 
blood vessel occlusion and is central to CM pathogenesis (4), 
immunological mechanisms operating during development of CM 
remain unclear. 
Accessibility to human tissues limits research into understanding 
the progression and control of CM development in humans (5). 
Therefore usage of the mouse model, termed Experimental 
Cerebral Malaria (ECM) has enabled researchers to uncover 
cellular and molecular components occurring in CM. Recent papers 
addressed the relevance of the mouse model of ECM and 
emphasized the need of denoting consistent factors between the 
mouse model and human studies (6-9). As such factors are seldom 
confirmed, confounding lists of players in CM development has 
emerged as a result. One factor however remaining implicit are 
CD8+ T cells (10, 11) although the exact mechanisms that drive 
CD8+ T cell pathogenesis in CM remain unclear. Additionally, the 
role of cytokines in human CM development have been brought to 
light in recent genetic studies [reviewed by (12)]. Initial reports by 
Hill and co-workers began exploring the necessary role of Type I 
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interferon (Type I IFN) with CM progression, and found genetic 
variants in IFNAR1 led to protection from CM development (13, 14). 
As IFNAR1 is the key signaling receptor mediating Type I IFN 
activity (15) and is expressed on virtually every cell surface (16, 
17), the impact Type I IFN has on the immune response is vast. In 
particular Type I IFN has been shown to be involved in the priming 
of CD8+ T cells (18, 19) and in the generation of a robust immune 
response to infection (20, 21). Recent publications address the 
actions of Type I IFN; through the IFNAR1 receptor, in response to 
hemozoin derivatives (22); and in controlling parasite burden upon 
Plasmodium infection(23). However, the exact caliber of IFNAR1 
action in CM development remains unexplored. 
We performed a genetic study to analyze IFNAR1 involvement in 
progression of CM vs uncomplicated malaria (UM). We selected 
children, the primary risk group of severe malaria, from an area of 
Angola where malaria transmission is perennial (24). We report 
here, variants of IFNAR1 strongly associate with CM protection, 
which drove the use of Ifnar1-/- mice, to interrogate the action of 
IFNAR1 in CM pathogenesis. We describe ECM protection in 
Ifnar1-/- mice and through design of a novel cell transfer protocol we 
expose the necessity of IFNAR1 expression in CD8+ T cells during 
development of ECM. 
3.4 Materials and Methods 
3.4.1 Patient and control samples 
A total of 272 children, living in Luanda and ranging from 6 
months to 13 years of age were enrolled in the present study. 
Ethical permission for this study was granted by the Ethical 
Committee of the Hospital Pediátrico David Bernardino (HPDB) in 
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Luanda, appointed by the Angolan Ministry of Health. Written, 
informed consent was obtained from the parents or guardians of 
each child. Patients were selected from attendees to the HPDB. 
The details of the dataset have been described previously (25). 
Briefly, samples were collected from children aged 6-156 months, 
carried out between February 2005 to May 2007 and comprised of 
130 patients with CM and 142 patients with UM. Malaria was 
diagnosed on the basis of a positive asexual parasitaemia detected 
on a Giemsa-stained thick smear (26). CM was defined according 
to the WHO criteria: a coma score < 3 on the Blantyre Scale for 
children < 60 months, or a coma score < 7 on the Glasgow Scale 
for children ' 60 months. Meningitis and encephalitis were ruled out 
by cerebrospinal fluid analysis after lumbar puncture. Exclusion 
criteria were different known aetiologies of encephalopathy and 
hypoglycaemia (glycaemia < 40 mg/dl).  Patients with 
consciousness disturbances or with other diseases were also 
excluded from this group. The UM group represents patients with 
malaria diagnosis and febrile illness without any clinical finding 
suggestive of other causes of infection and with no manifestations 
of severe malaria.  
3.4.2 Genotyping 
Genomic DNA was extracted from whole blood using the 
Chemagen Magnetic Bead technology. DNA preparations were 
quantified using PicoGreen reagents according to the supplier 
instructions. 27 SNPs covering the IFNAR1 region were initially 
genotyped using the Sequenom's iPlex assay (San Diego, USA) 
and the Sequenom MassArray K2 platform performed by the 
Genomics Unit of the Instituto Gulbenkian de Ciência.  
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Extensive quality control was performed using eight 
HapMap (http://hapmap.ncbi.nlm.nih.gov/) controls of diverse 
ethnicity, Hardy-Weinberg equilibrium (HWE) with P > 0.01, and a 
minimum of 90% call rate for each SNP. Genotype determinations 
were performed blinded to affection status. Only SNPs with minor 
allele frequency > 1% in both groups were analyzed for association. 
Nine SNPs in IFNAR1 (rs224359, rs2252930, rs12626750, 
rs2834197, rs2226300, rs2254315, rs1012943, 2843996 and 
2254305) did not meet the quality control criteria and were 
excluded. Samples with < 75% call rate and duplicates were 
excluded from analysis, a total of 33 samples were excluded. The 
final dataset used in the analysis consisted of 239 children 
comprising 110 CM cases (mean age 54.6 months) and 129 UM 
(mean age 49.1 months) patients. 
3.4.3 Association testing 
(2 tests for HWE in both groups, allelic and haplotypic 
association of SNPs with progression to CM, and linkage 
disequilibrium (LD) plots were performed using Haploview 4.2 (27). 
Diagram with representation of allelic genetic association results 
was produced by the snp.plotter R package (28). Association 
analyses were performed with logistic regression and adjusted for 
potential confounding effects of age using the SNPassoc v.1.4-9 
package (29) implemented in the R freeware (http://cran.r-
project.org/). Results were considered suggestive below the 
conventional probability level of 0.05. Bonferroni corrections for 
multiple tests were carried out to exclude type I errors (the 
significance level for 18 tests is set at P value < 2.78 E)3).  
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3.4.4 Animals 
Male, 8-12 weeks old C57BL/6, B6.Ly5.1, Ifnar1-/- and 
BALB/c mice were bred and used as provided by the Instituto 
Gulbenkian de Ciência in-house animal facility. Ifnar1-/- mice were 
originally a gift to the institute from Michel Aquet (Ifnar1-tm-Agt) (30). 
Ifnar1-/- mice have been backcrossed into the C57BL/6 background, 
(98.7% - 99.36% C57BL/6 background outside of the congenic 
region, as confirmed by the animal facility at Instituto Gulbenkian de 
Ciência). All procedures were in accordance with national 
regulations on animal experimentation and welfare as approved by 
the Instituto Gulbenkian de Ciência Ethics committee.  
3.4.5 Parasite, infection and ECM disease 
assessment 
All infections used 1 % 106 P.berghei ANKA-GFP parasitized 
iRBC (31) given via i.p injection. Frozen iRBC stocks were 
expanded in C57BL/6 mice prior to infection. Parasitemia was 
determined as the % of GFP+ red blood cells, using flow cytometry 
analysis (FacScan Cell Analyser, Becton Dickinson, New Jersey) 
and non-infected RBCs as negative control. ECM development was 
monitored from day 5 post-infection (PI) as including; head 
deviations, paralysis, ataxia and convulsions (32). ECM susceptible 
mice developed symptoms at days 6-7 post-infection and died 
within 4-5 hours. Mice resistant to ECM died around days 22-25 
from anemia and hyperparasitemia without displaying neurological 
symptoms. 
3.4.6 Blood brain barrier (BBB) integrity 
Upon display of ECM induced coma in C57BL/6 mice, the 
experimental groups of mice were successively injected with 100 µl 
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of 2% Evan’s blue dye (Sigma), sacrificed one hour post injection 
and perfused intracardially with 15 ml ice-cold PBS. Brains were 
dissected, weighed and immersed in 2 ml formamide (Merck) 
covered at 37 °C for 48 h, to allow extraction of Evan’s blue dye, 
images were taken after the 48 h period. Non-infected mice from 
each group were used as controls. Absorbance of dye was 
measured at wavelengths 620 nm and 740 nm using 
Spectrophotometry, (ThermoSpectronic, Helios Delta). Using a 
standard curve, data was calculated and expressed as µg of Evans 
blue dye/mg of brain tissue.  
3.4.7 Histology 
Infected C57BL/6 and Ifnar1-/- mice were sacrificed upon 
observation of clinical signs of ECM in C57BL/6 mice, around day 6 
post-infection. Non-infected C57BL/6 and Ifnar1-/- mice were used 
as controls and sacrificed at the same time point. For hematoxylin 
and eosin (H&E) staining; brains were carefully removed, fixed in 
10% neutral-buffered formalin, embedded, sectioned (4 µm) and 
mounted with entellan (Merck, Darmstadt, Germany) then finally 
stained with Hematoxylin and Eosin following standard procedures. 
CM and brain pathology were assessed by routine histopathology in 
coronal brain sections of the same anatomical location. Bright field 
images were captured utilizing a Leica DMD108 microscope 
(LeicaMicrosystems), 10 % (numerical aperture: 0.40) and 40 % 
(numerical aperture: 0.95) objectives were employed. Adobe 
Photoshop software was utilized to compose images and adjust the 
contrast (Adobe, USA). 
3.4.8 Gene expression 
 C57BL/6 and Ifnar1-/- infected mice were sacrificed at days 5, 
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6, and 7 post-infection. Ifnar1-/- mice were sacrificed further at days 
9 and 11 post-infection, C57BL/6 mice were not collected at these 
time points due to death from ECM. Non-infected C57BL/6 and 
Ifnar1-/- mice were used as controls and represent day 0. Brains 
were dissected, fast frozen in liquid nitrogen and stored at -80 °C. 
Brains were then homogenized and a final brain weight of 20 mg 
was used for total RNA extraction (RNeasy® Mini Kit, Qiagen). 
RNA quality was determined using Nanodrop and a final elution of 
50 µl extracted. One microgram of total RNA was converted to 
cDNA (Transcriptor High Fidelity cDNA Synthesis Kit, Roche) using 
random hexamer primers and a final volume of 10 µl of the cDNA 
reaction was diluted 1:3 in RNAse-free water to be used for mRNA 
quantification. Tnf-#, Il-10 mRNA was quantified using TaqMan® 
Gene Expression Assays from ABI (Mm00443258_m1 and 
Mm99999062_m1, respectively). Plasmodium berghei ANKA rRNA 
was quantified using specific primer sequences: Forward 5’-CCG 
ATA ACG AAC GAG ATC TTA ACC T-3’, Reverse 5’-CGT CAA 
AAC CAA TCT CCC AAT AAA GG-3’ and Probe 5’-ACT CGC CGC 
TAA TTA G-3’ (FAM/MGB), all with Taqman® Universal PCR 
Master Mix. T lymphocyte (Cd3e) expression was quantified using 
specific primer sequence: Forward 5’-TCT CGG AAG TCG AGG 
ACA GT-3’ Reverse 5’-ATC AGC AAG CCC AGA GTG AT-3’ (33), 
using Power SYBR Green PCR Master Mix (Applied Biosystems). 
Gene expression quantification reactions were performed on an ABI 
Prism 7900HT system according to manufacturers’ instructions, a 
total volume of 10 µl PCR reactions was amplified for 45 cycles. 
Relative quantification of specific mRNA was normalized to the 
mouse housekeeping gene ACTB (Mouse ACTB Endogenous 
Controls, ABI), used in multiplex PCR with the target genes and 
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calculated using the **Ct method. 
3.4.9 Pre-Sensitization protocol  
For infected blood donor mice; blood was collected by 
mandibular vein puncture into an eppendorf containing 10 µl of 
Heparin (Heparina Leo, Leo Pharmaceutical products) from infected 
mouse at day 6 post-infection, upon display of ECM symptoms and 
when parasitemia was around 30%. Parasitemia was measured to 
calculate injection of 4 % 106 iRBC into cell donor mice. Collected 
blood was then placed on ice in a 50 ml falcon tube and irradiated 
at 20 k Rad (GAMMACELL 2000, MØLSGAARD Medical 
Denmark). Irradiated iRBC were then re-suspended in PBS and 
injected i.p into cell donor mice. At day 6 post irradiated-iRBC 
injection, cell donor mice were sacrificed and purified spleen cell 
populations were injected into recipient mice; recipient mice were 
left either non-infected (NI) or infected 1 % 106 PbA i.p one hour 
after transfer. Parasitemia and ECM development were monitored 
from day 5 post-infection. For control non-infected blood donor 
mice; mice were bled and an equivalent volume of non-infected 
RBC were irradiated and diluted in PBS in the same manner as 
above.  
3.4.10 Spleen cell transfers 
Single cell suspensions were prepared from spleens of cell donor 
mice. For total spleen cell transfers; cells were washed 2 % in PBS, 
counted in a hemocytometer, re-suspended in PBS and injected 
5 %106/ 100 µl into recipient mice. For spleen CD8+ cell transfers; 
cells were washed 2 % in PBS 2%FCS and incubated with anti-
mouse CD8-alexa647 antibody (clone YTS169, in house 
production), for 30 min on ice. For CD8+Ly5.1/2+ cell transfers; cells 
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were incubated with anti-mouse CD8-alexa647 antibody (clone 
YTS169, in house production), anti-mouse CD45.1-FITC antibody 
(clone 820, BD Pharmingen) or anti-mouse CD45.2-PE antibody 
(clone 104.2, in house production) for 30 min on ice. Stained cells 
were washed in PBS 2%FCS and sorted (FacsAria Multicolour Cell 
Sorter, Becton Dickinson, New Jersey) by combining lymphocyte 
morphological gating and relevant antibody labels.  
For CD8+ transfers; cells were collected as purified CD8+ 
cells and CD8- (depleted) groups of cells. For CD8+Ly5.1/2 
transfers; cells were gated for CD8+ cells within which CD45.1+ or 
CD45.2+ populations were collected. Purified cell populations were 
washed in PBS and counted. Cells were injected intravenously (i.v) 
3 % 106/ 100 µl into recipient mice. Respective groups of recipient 
mice were then infected 1 % 106 iRBC/ 100 µl PbA one hour after 
cell transfer. Mice were monitored for parasitemia and ECM 
development from day 5 post-infection. 
3.4.11 Analysis of spleen cells 
Single cell suspensions were prepared from spleens of 
C57BL/6 and Ifnar1-/- infected mice at day 5 post-infection, non-
infected mice from both groups were used as control. Cells used for 
total cell counts and activation profile were prepared as single cell 
suspensions: from 5ml of total cells, 200 µl per sample was plated 
in a 96 round well plate, cells were centrifuged, pelleted and re-
suspended in Fc Block for 20 min on ice, cells were then washed in 
PBS, 2%FCS, and re-suspended in either: anti-mouse CD8-
alexa647 antibody (clone YTS169, in-house antibody) or CD4-
alexa647 (clone GK 1.5, inhouse antibody) with CD44-FITC (clone 
IM7, BD Pharmingen 553133) and CD62L-PE (clone Mel 14, 
eBioscience 12-0621-85) for 20 min on ice. Cells were then 
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washed, resuspended in 100 µl PBS, 2%FCS, plus 20 µl propidium 
iodide (1µg/ml) (Sigma, P-4170), plus 10 µl 5 % 105 beads 
(Beckman Coulter ® nominal 10µm Latex Beads). For intracellular 
stainings: cells were then washed and re-suspended in red blood 
cell lysis, then washed and re-suspended in 100 µl RPMI medium 
supplemented with 10% FCS, 10 U/ml Pen-Strep, 1% sodium 
pyruvate, 1% HEPES 1+, 1% L-Glutamine, 0.01% #-
Mercaptoethanol, centrifuged and finally re-suspended in 200 µl 
RPMI supplemented medium containing 10 µg/ml of Brefeldin A for 
fixation of cytokine production, 100 ng/ml of PMA and 500 ng/ml of 
Ionomycin for cell stimulation. Cells were stimulated at 37 °C, 5% 
CO2 for 4 hours. Cells were then processed for extracellular 
staining; cells were centrifuged, pelleted and re-suspended in Fc 
Block for 20 min on ice, cells were then washed in PBS, 2%FCS, 
and re-suspended in anti-mouse CD8-alexa647 antibody (clone 
YTS169, in house antibody) for 20 min on ice. Cells were then 
washed and re-suspended in 2%PFA for fixation for 30min at room 
temperature (RT), then washed 2 % in PBS and re-suspended in 
200 µl PBS, 2%FCS and stored at 4 °C overnight. The proceeding 
day, cells were pelleted, re-suspended in permeabilisation buffer 
(10% Saponin in PBS, 2%FCS) for 10 min at RT in preparation for 
intracellular staining. Cells were then washed and pelleted and 
incubated with anti-mouse GranzymeB-FITC (clone NGZB, 
eBioscience) and anti mouse IFN-!-PE (clone XMG1.2, BD 
Pharmingen) for 30 min at RT. Cells were then washed 2 % in 
permeabilisation buffer and then 2 % in PBS, 2%FCS and re-
suspended in 150 µl PBS, 2%FCS plus 5 % 105 beads (as before). 
All cell analysis was performed using FacsCalibur cell analyzer, and 
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FlowJo (version 7). Single staining preparations were used for 
control compensation of double staining analysis.  
3.4.12 Analysis of brain-sequestered leukocytes 
C57BL/6 and Ifnar1-/- infected mice were sacrificed at day 6 
post-infection, perfused pericardially (as described above) and 
brains placed in 10 ml of HBSS supplemented with Collagenase 
VIII (Sigma-Aldrich), 0.2 mg/ml. Brains were then smashed and 
incubated for 30 min at 37 °C. Each sample was passed through a 
100 µm strainer and centrifuged for 10 min at 1500 rpm. 
Supernatant was discarded and samples re-suspended in 10 ml 
PBS and centrifuged. Samples were re-suspended in 10 ml of 30% 
Percoll gradient (PercollTM, GE Healthcare, BioSciences) and 
centrifuged for 20 min at 2500 rpm at RT, without brake. The 
supernatant was carefully aspirated and pellet re-suspended in 50 
ml of PBS and centrifuged. The supernatant was discarded and 
each sample pellet re-suspended to a final volume of 200 µl. Cells 
were centrifuged and re-suspended in 100 µl red blood cell lysis, 
incubated for 5 min at RT, washed 2 % in 200 µl PBS, 2%FCS and 
re-suspended in supplemented RPMI medium and proceeded for 
extra and intracellular staining and analysis as described above. 
 
3.5 Results 
3.5.1 IFNAR1 variants are associated with protection 
against clinical progression to cerebral malaria  
The IFNAR1 gene has been associated to severe forms of 
malaria (13, 14). Here we made use of a cohort of Angolan children 
to identify IFNAR1 genetic variants that specifically modify the risk 
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of progressing to CM syndrome from uncomplicated forms of 
malaria.  We compared genotype frequencies of single nucleotide 
polymorphisms (SNPs) in infected children that developed CM 
(n  = 110) vs children that presented clinically uncomplicated 
malaria (UM) (n = 129). After age correction, eight out of 18 
IFNAR1 SNPs showed suggestive association (P < 0.05) with 
progression to CM (Figure 3.1b) - possibly under a dominant mode 
of action (Appendix Two, Table S1). The two markers having the 
strongest association with progression to CM, rs2856968 
(P = 1.33E)6) and rs2253923 (P = 5.77E)5), remained significantly 
associated after conservative Bonferroni correction for multiple 
testing (P < 2.78E)3) (Figure 3.1b). As the two SNPs are in strong 
linkage disequilibrium (LD) (r2 = 0.77) this result suggests a single 
genetic effect in CM protection (Figure 3.1c). 
Haplotypic association analysis comprising eight SNPs in 
the 5’ region of IFNAR1 (encompassing upstream regulatory region 
intron 1 and intron 2), identified one haplotype that shows robust 
association to CM protection (Phap = 6.89E)7; ORhap = 0.34). 
Conversely, the most frequent haplotype for the same eight SNPs 
shows an increased risk of CM progression (Phap = 8.0E)4; 
ORhap = 1.87). 
Together this genetic evidence strongly suggests that 
specific minor frequency alleles of IFNAR1 gene provide protection 
against CM. This proposes a determinant role of IFNAR1 during the 
inflammatory response to malaria infection and specifically at 
dictating progression to CM. 
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Figure 3.1 IFNAR1 gene variants protect against malaria 
progression to cerebral malaria syndrome. Results of genotypic 
association tests under the dominant model at 18 IFNAR1 SNPs, 
depicted at the bottom of the horizontal axis according to relative 
physical distance(a) Scaled diagram of the IFNAR1 gene structure: 
exons are marked with their corresponding number; 5’UTR and 
3’UTR are represented by gray boxes; introns are represented by 
black lines between exons. (b) Genotypic P-value of association 
tests were obtained by comparing 110 cases of cerebral malaria 
(CM) with 129 uncomplicated malaria patients (UM) using logistic 
regression and adjusted for age. Thresholds for suggestive 
association (P = 0.05) and for significant association after multiple 
testing Bonferroni correction (P = 2.78 E)3) are represented. (c)  
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3.5.2 Ifnar1-/- mice are protected from development of 
Experimental Cerebral Malaria and brain pathology 
To ascertain whether IFNAR1 is involved in inflammation 
evoked by malaria infection we used the mouse model of ECM (6). 
In line with a recent report (22) we observed that P.berghei ANKA 
(PbA) infection in Ifnar1-/- mice led to strong resistance to ECM 
(75% ECM resistance, Figure 3.2a) in comparison to susceptible 
C57BL/6 control mice. Ifnar1-/- mice that resisted to ECM 
development, die between days 25-30 from anemia and 
hyperparasitemia and showed parasitemia comparable to C57BL/6 
mice, up to day 5 post-infection (Figure 3.2b). This indicated that 
ECM resistance in Ifnar1-/- mice was not related to decreased 
peripheral parasite burden. 
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Figure 3.2 Ifnar1-/- mice are protected from ECM and show no 
decrease in parasite burden. C57BL/6 (filled squares) and Ifnar1-/- 
(open squares) mice were infected with 1 % 106 P.berghei ANKA-
GFP (PbA) infected red blood cells (iRBC) via intraperitoneal (i.p) 
injection. (a) Survival curve; (n = 17, log-rank test). (b) Parasitemia 
progression; (n = 17, unpaired, two tailed t-test; day 6 post-infection 
(PI); **P = 0.0016, day 7 PI; **P = 0.0021). Data collective from at 
least four independent experiments. Time window of C57BL/6 ECM 
development is shadowed. 
 
 
Disruption of the blood brain barrier (BBB) is a standard 
hallmark of ECM pathology (34). We analyzed infected and non-
infected C57BL/6, Ifnar1-/- as well as ECM resistant BALB/c mice 
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for barrier breakage using Evans blue. Alike BALB/c mice, Ifnar1-/- 
mice display no BBB breakage (Figure 3.3a and b) as opposed to 
C57BL/6 mice that showed abundant dye leakage in the brain. 
Histopathological analysis of infected C57BL/6 brain sections 
exhibited: prominent mononuclear cell accumulations within brain 
micro-vessels (Figure 3.3d); evidence of disruption of vessel walls 
and endothelial cell destruction (Figure 3.3e); as well as 
parenchymal hemorrhagic lesions containing infected red blood 
cells (iRBCs) (Figure 3.3f). In contrast, ECM resistant Ifnar1-/- mice 
displayed: mild intravascular accumulation of mononuclear cells 
(Figure 3.3h); intact endothelial cells (Figure 3.3i) and absence of 
hemorrhagic lesions with iRBCs seen within the lumen of blood 
vessels only (Figure 3.3j).  These results show that despite 
abnormal mononuclear accumulation within brain micro-vessels 
and presence of intra-luminal iRBCs, infected Ifnar1-/- mice do not 
show typical pathology of ECM. 
 
Figure 3.3 Ifnar1-/- mice are protected from BBB breakage and 
show reduced mononuclear cell accumulation in brain 
microvasculature. C57BL/6, Ifnar1-/- and BALB/c mice were 
infected with 1 % 106 PbA iRBC i.p and analyzed at day 6 PI. (a) 
BBB integrity was assessed in all infected groups of mice by Evan’s 
Blue perfusion. Non-infected mice from each group were used as 
controls; (n = 3-5 mice per group). Images representative of two 
independent experiments. (b) Quantification of Evan’s Blue dye was 
measured as µg of dye/mg of brain tissue; (n = 3-4 mice per group, 
ANOVA, Tukey’s Multiple Comparison Test; ***P & 0.001). Data 
representative of two independent experiments. (c-j) H&E staining 
of brain sections from C57BL/6 and Ifnar1-/- mice, (non-infected 
mice were used as controls). Mice were sacrificed upon display of 
ECM in C57BL/6 mice. Coronal sections of brain microvasculature 
and mononuclear cell accumulation in; non-infected C57BL/6 mice 
(c), infected C57BL/6 mice (d-f), non-infected Ifnar1-/- mice (g), 
infected Ifnar1-/- mice (h-j); magnification % 400, scale bar 30 ,m. 
Coronal sections of infected C57BL/6 mice; showing absence of 
endothelial cells (e, arrows) and presence of hemorrhagic foci with 
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iRBCs (f, arrowhead). Sections of infected Ifnar1-/- mice; showing 
intact endothelial cells (j, arrow), and intra-luminal iRBCs (i and j, 
arrowhead); magnification % 1000, scale bar 30 ,m. Images 
representative of three mice examined per group. 
(Figure presented on the next page).  
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3.5.3 Ifnar1-/- mice display a delayed brain 
inflammatory response upon infection 
To further investigate the mechanisms underlying ECM 
protection in Ifnar1-/- mice, we evaluated cytokine production and 
parasite burden within the brain tissue of C57BL/6 and Ifnar1-/- 
infected mice. Comparison of P. berghei rRNA quantification 
showed no significant differences during the early time course of 
infection, strongly suggesting that ECM protection in Ifnar1-/- mice 
was not attributable to reduced brain parasite burden (Figure 3.4a). 
We also observed that kinetics of Cd3 mRNA expression in the 
brain leading up to ECM manifestations was slightly lower in Ifnar1-/- 
mice but not significantly different from C57BL/6 mice. This 
suggests that T cell migration to the brain during infection was not 
impaired in Ifnar1-/- mice (Figure 3.4b). Nevertheless, we found that 
in the brain of Ifnar1-/- mice the expression of inflammatory markers, 
namely Tnf and Il10 had lower induction in the period preceding 
ECM onset and showed delayed kinetics as compared to C57BL/6 
infected mice. Overall, these results indicate that in spite the 
accumulation of iRBCs and presence of T cells, Ifnar1-/- mice show 
a diminished exacerbation in their inflammatory responses, 
deterring the development of brain pathology within the time 
window of ECM development. 
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Figure 3.4 Parasite accumulation and brain inflammation 
markers in Ifnar1-/- infected mice. C57BL/6 (black bars) and 
Ifnar1-/- mice (white bars) were infected 1 ! 106 PbA iRBC, i.p. and 
brain RNA extracted at indicated time points for RT-PCR 
quantification. (a) P.berghei rRNA relative quantification; (day 5 
infected C57BL/6 mice used as calibrator), expression of (b) Cd3; 
(c) Tnf-! and (d) Il-10; (non-infected C57BL/6 mice used as 
calibrator, represented as day 0); (n = 3-4 mice per group/per day, 
non-parametric Mann Whitney test. Data presents means ± SD 
from one of two independent experiments. Time window of 
C57BL/6 ECM onset is shadowed. 
 
 
3.5.4 Pre-sensitization for cell transfer 
We questioned in which cell type IFNAR1 was fundamental 
to cause ECM development in mice. To this end we developed a 
novel cell transfer protocol to determine the ability of individual cell 
types at restoring ECM susceptibility in Ifnar1-/- mice (Figure 3.5a). 
Donor mice were exposed to irradiated iRBC allowing relevant 
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blood-stage parasite antigens (Ag) to prime in vivo immune system 
cells that were then used in transfer experiments. The irradiated 
parasite is unable to re-invade RBC, and therefore (exposed) donor 
mice do not develop parasitemia or ECM. We analyzed the T cell 
profiles of C57BL/6 mice that received iRBC against mice that 
received irradiated iRBC (Figure 3.5b, c). We found that CD8+ T 
cells numbers of mice that received irradiated iRBC did not reach 
as high as that found in infected C57BL/6 mice, but showed similar 
numbers of activated CD8+ T cells (CD44hi and CD62Llow) (Figure 
3.5b). We noted that CD4+ T cell numbers and activation profile 
were not significantly different between mice that received either 
irradiated iRBC vs iRBC (Figure 3.5c). Together this suggests that 
irradiated iRBC induces activation of both CD8+ and CD4+ T cells. A 
group of C57BL/6 cell donor mice were injected with irradiated 
iRBC and then infected with 1!106 non-irradiated PbA iRBC 7 days 
later, (as per normal infection); all mice subsequently developed 
ECM and died by day 7 post-infection (data not shown). We 
concluded that our protocol is not conferring protective immunity but 
is rather a protocol of immune cells pre-sensitization that occurs in 
absence of parasite expansion or disease development. We 
anticipate this method to be useful in investigating immuno-
pathogenesis of malaria blood stage in future mouse models. 
 
Figure 3.5 Ifnar1-/- mice succumb to ECM upon cell transfer of 
parasite-sensitized splenocytes; explicitly CD8+ cells. (a) 
Schematic representation of pre-sensitization protocol: as 
described in Methods. (b) Total number and activation profile of 
C57BL/6 mice splenic CD8+ and (c) CD4+ T cells at 5 days post-
challenge; non-infected NI (black bar), infected 1 ! 106 PbA i.p 
(grey bar) or injected 4 ! 106 irradiated iRBC i.p (lined bar); (n = 4-6 
mice per group, non-parametric Mann Whitney test; *P " 0.05, 
**P " 0.01). Parasitemia and survival curves of Ifnar1-/- mice: (d) 
that received total spleen cells from C57BL/6 pre-exposed donor 
! ""&!
mice, recipients were infected after transfer (open squares) or left 
non-infected (closed squares); (e and f) that received sorted pre-
sensitized CD8+ spleen cells (open squares) or sorted pre-
sensitized CD8- depleted spleen cells (open circles) from C57BL/6 
pre-exposed cell donor mice (e) or Ifnar1-/- pre-exposed cell donor 
mice (f), transfer control represents infected Ifnar1-/- mice that 
received no cells (diamonds); (n = 4-6 mice per group, parasitemia; 
unpaired t-test, survival curves; Log-rank Test, (e: open squares vs 
open circles); all significant differences displayed). Each plot 
represents one of at least two independent experiments. Time 
window of ECM, shadowed in survival plots. (g) Measurement of 
BBB breakage by Evans Blue perfusion in recipient Ifnarl-/- mice, as 
in (e); (n = 3-4 per group). (h) Quantification of Evan’s Blue dye; (n 
= 3-4 per group, ANOVA, Tukey’s Multiple Comparison Test; 
**P " 0.01, ***P " 0.001). Data (g and h) represent one of two 
independent experiments.  
(Figure presented on next page). 
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3.5.5 C57BL/6 spleen cells confer ECM susceptibility 
to Ifnar1-/- mice 
Total splenocytes were transferred from C57BL/6 mice that 
had received irradiated iRBC (cell donors), to Ifnar1-/- mice. Upon 
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infection, recipient Ifnar1-/- mice showed 75% development of ECM, 
6-12 days post-infection, within the ECM time window of 
susceptible C57BL/6 mice (Figure 3.5d). This demonstrates that 
C57BL/6 splenocytes pre-sensitized to irradiated iRBC are effective 
at restoring ECM susceptibility in Ifnar1-/- mice. In a control 
experiment, total splenocytes were transferred from C57BL/6 cell 
donor mice that had received non-infected irradiated RBC to Ifnar1-
/- mice. When infected one hour post-transfer, recipient mice 
developed parasitemia alike Ifnar1-/- mice that received infection 
only (no cell transfer). Neither group of mice developed ECM, with 
all mice dying around day 25 post-infection from anemia and 
hyperparasitemia (Appendix Three, Figure S1). This shows that 
C57BL/6 splenocytes exposed to non-infected irradiated RBC are 
unable to induce ECM susceptibility in Ifnar1-/- mice indicating that 
RBC irradiation per se has no impact on ECM development in 
recipient mice. We then determined whether CD8+ spleen cells 
induced ECM in Ifnar1-/- mice. Sorted CD8+ or CD8- depleted cells, 
isolated from donor C57BL/6 mice that received irradiated iRBC, 
were transferred into Ifnar1-/- mice (Figure 3.5e). Recipient mice 
were then infected one hour after cell transfer. Parasitemia did not 
differ between the two groups of mice when compared against 
Ifnar1-/- mice that received infection only (and no cell transfer). In 
contrast, we found ECM development in only the group of Ifnar1-/- 
mice that received purified CD8+ cells. This result indicate that 
transfer of pre-sensitized C57BL/6 CD8+ cells is sufficient to restore 
susceptibility to ECM in Ifnar1-/- mice. Upon transfer of pre-
sensitized Ifnar1-/- CD8+ T cells to Ifnar1-/- mice, we found that 
recipient mice were not able to develop ECM, concluding that only 
CD8+ IFNAR1+ cells, from C57BL/6 exposed mice were able to 
cause ECM development (Figure 3.5f). By assessing BBB integrity, 
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we confirmed the ability of pre-sensitized CD8+ cells, isolated from 
C57BL/6 mice at inducing bone fide ECM. We observed BBB 
breakage only in Ifnar1-/- mice that received C57BL/6 CD8+ cells, 
but not in CD8-depleted cell recipient mice, (Figure 3.5g-h). 
Together these results show that IFNAR1 is critical for CD8+ cell 
mediated abrogation of ECM resistance in Ifnar1-/- mice. 
 
3.5.6 Intrinsic CD8+ T cell properties trigger ECM 
development 
To ascertain whether ECM induction was dependent on IFNAR1 
expression in CD8+cells we modified our cell transfer protocol 
(Figure 3.6a). CD8+ cells were sorted from non-infected Ifnar1-/-
.Ly5.2 mice and transferred to previously non-lethally irradiated 
C57BL/6.Ly5.1 mice; allowing for the discrimination of endogenous 
and transferred CD8+ populations. Ly5.1/5.2 chimeric mice then 
received irradiated iRBCs from a B6.Ly5.1 mouse. Seven days later 
Ly5.1 CD8+ and Ly5.2 CD8+ cell populations were sorted (Figure 
3.6b) and transferred to Ifnar1-/- recipient mice. No differences in 
parasitemia progression were observed in either group, as 
compared to Ifnar1-/- mice that received no cell transfer and 
infection only (Figure 3.6c). 
Conclusively we found that only recipient Ifnar1-/- mice that 
had received Ly5.1 IFNAR1+ CD8+ cells developed ECM, showing 
100% disease incidence, while recipients of Ly5.2 IFNAR1# CD8+ 
cells maintained ECM resistance comparable to Ifnar1-/- mice that 
received no cell transfer and infection only. This strongly suggests 
that deficiency in IFNAR1 signaling in CD8+ cells impairs their 
ability to induce ECM in Ifnar1-/- mice during PbA infection. 
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Figure 3.6. Intrinsic Ifnar1-/- CD8+ cell impairment protects from 
ECM. 
(a) Schematic representation of experimental protocol: Non-infected 
Ifnar1-/- mice were used as donors of 5 ! 106 CD8+Ly5.2+ spleen 
cells that were transferred to previously non-lethally irradiated 
B6.Ly5.1 recipient mice. Six days post transfer Ly5.1/Ly5.2 chimeric 
mice received 4 ! 106 irradiated iRBC, from a previously infected 
B6.Ly5.1 mouse. Seven days after iRBC infection, CD8+Ly5.2+ and 
CD8+Ly5.1+ spleen cells were FACS-sorted (b) as described in the 
methods section. The sorted CD8+ cell populations were injected 
back into Ifnar1-/- recipients, mice were then infected 1 ! 106 iRBC 
one hour after cell transfer. (c) Parasitemia and survival curves of 
Ifnar1-/- recipient mice that received from pre-exposed chimeras 
either: CD8+Ly5.1+ (filled squares); CD8+Ly5.2+ cells (open 
squares); or no cell transfer and infection only as control (open 
diamonds); (n = 3-12 mice per group, parasitemia; unpaired t-test 
between CD8+Ly5.1+ and CD8+Ly5.2+ recipient groups; *P " 0.05, 
survival curves; Log-rank Test, filled squares against open 
squares). Data pooled from three independent experiments. Time 
window of C57BL/6 ECM symptoms is shadowed in survival plot. 
(Figure presented on next page). 
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3.5.7 Ifnar1-/- mice display differing activation states 
in spleen and brain tissue compared to C57BL/6 mice  
To investigate CD8+ T cell impairments in Ifnar1-/- mice 
during PbA infection we analyzed the activation and expansion of 
CD8+ T cells in the spleen at day 5 post-infection, prior to ECM 
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onset. We found a significant difference between non-infected 
C57BL/6 and Ifnar1-/- mice; that was attenuated upon infection. This 
indicates that infection-driven CD8+ T cell expansion was not 
impaired in Ifnar1-/- mice (Figure 3.7a). Similarly, splenic CD8+ T 
cells from Ifnar1-/- mice do not show impairments in Granzyme B 
(GrB) or Interferon gamma (IFN-$) expression upon infection 
(Figure 3.7b and c). We also note that CD4+ T cell expansion and 
activation, as measured by IFN-$, is not hindered in Ifnar1-/- mice 
upon infection, as compared to C57BL/6 mice (Appendix Four, 
Figure S2). 
Likewise, we analyzed profiles of CD8+ T cells from the 
brain of C57BL/6 and Ifnar1-/- infected mice at day 6 post-infection, 
upon display of end stage ECM symptoms in control C57BL/6 mice. 
We found that total number of CD8+ T cells sequestered in the brain 
of Ifnar1-/- mice was significantly reduced, as compared to C57BL/6 
mice (Figure 3.7d). Nevertheless, the vast majority of brain 
sequestered CD8+ T cells in both Ifnar1-/- and C57BL/6 mice were 
activated and showed a cytotoxic profile  (Figure 3.7e and f). This 
indicates no faltering in sequestered Ifnar1-/- CD8+ T cells to exhibit 
a cytotoxic profile, as supported by mean fluorescence intensity 
analysis of GrB and IFN-$ in CD8+ T cells upon infection, as 
compared to C57BL/6 (Appendix Five, Figure S3). 
We confirmed these results by analyzing sequestered CD8+ 
T cells at day 6 post-infection, from Ifnar1-/- mice that received 
either CD8+ T cells, (and were restored with ECM susceptibility) or 
CD8- depleted cells.  As expected, higher numbers of CD8+ T cells 
as well as GrB+ and IFN-$+ CD8+ T cells were seen in the brain of 
mice that received CD8+ T cell transfer (Figure 3.7g-i). However 
these results were not significantly different, suggesting that 
induction of ECM in Ifnar1-/- mice is not strictly dependent on 
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accumulation of effector IFNAR1+ CD8+ T cells. Together these 
results suggest that ECM resistance in Ifnar1-/- mice operates 
through impaired IFNAR1 signaling in CD8+ T cells. 
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Figure 3.7 IFNAR1- CD8+ T cells show activation upon infection 
but not accumulation in the brain. Numbers of CD8+ T cells, 
GrB+ CD8+ T cells, and IFN-$+ CD8+ T cells of infected and non-
infected C57BL/6 and Ifnar1-/- mice: (a-c) in the spleen; (d-f) in 
perfused brains; (g-i) in perfused brains of Ifnar1-/- recipient mice 
that received sorted CD8+ or CD8- depleted spleen cells from pre 
exposed C57BL/6 donor mice. Mice were analysed for CD8+ T cells 
in the spleen on day 5 PI and in the brain on day 6 PI when 
C57BL/6 or Ifnar1-/- ECM induced-mice displayed symptoms of 
ECM development; (n = 3-5 mice per group, non-parametric Mann 
Whitney test; *P " 0.05, **P " 0.01; all statistically significant 
differences are shown). Data is representative of three (a-f) or two 
(g-i) independent experiments performed. (b: C57BL/6 non-infected 
group mean; 2.8 ! 105, Ifnar1-/- non-infected group mean; 
8.0 ! 104).  
 
 
3.6 Discussion 
This work strengthens the role of Type I interferons/IFNAR1 
signaling in human cerebral malaria and uncovers the actions of 
IFNAR1 in ECM development. We found that IFNAR1 genetic 
variants showed protection against progression to CM in a 
population of Angolan children. In Gambian children, two SNPs 
were identified in the IFNAR1 gene, in intron 3 and exon 4, that 
were associated with severe malaria and CM cases (13). However 
the study embarking Gambian, Kenyan and Vietnamese 
populations (14) highlighted positive associations in the 5’ region of 
the IFNAR1 locus. This was also found as a region of strong 
association in our study, suggesting that the 5’ region of the 
IFNAR1 gene-known to control transcriptional activity (35), 
represents a malaria susceptibility factor throughout diverse 
populations. Furthermore, the design established in our study 
proved to be advantageous, allowing us to evaluate specifically the 
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association of IFNAR1 to disease progression, from uncomplicated 
malaria to cerebral malaria. IFNAR1 has also been associated with 
AIDS progression (15) and clinical presentation of hepatitis B virus 
infection (36), this allows the inference that IFNAR1 variants can 
impact on Type I IFN responses, and govern the course and 
progression of infectious diseases. 
These results motivated the use of Ifnar1-/- mice to address the 
mechanisms underlying the pathogenesis of CM using the ECM 
mouse model. We found that protection from ECM in Ifnar1-/- mice 
was not controlled via a reduction in parasite burden. Conflicting 
results show no decrease in parasitemia, found when using PbA 
infection in Ifnar1-/- mice (22); vs a decrease in parasite burden, 
upon PbA GFP +luciferase infection (23). Although, it remains to be 
determined whether differing strains of PbA parasite dictate 
parasitemia burden in Ifnar1-/- mice infection. In our experimental 
system (PbA-GFP), Type I IFN appears to be dominant during other 
stages of ECM pathogenesis. Despite rapid and steep development 
of parasitemia throughout infection and parasite accumulation 
within the brain tissue-at comparable levels to susceptible C57BL/6 
mice-this was not enough to provoke a sufficient inflammatory 
response for BBB breakage and mononuclear cell accumulation 
within brain micro-vessels. It is worth mentioning that recombinant 
human IFN-alpha evoked a striking reduction on parasite burden 
and protection from ECM in C57BL/6 mice, suggesting that the 
Type I IFN/IFNAR1 system has a role in parasite development (37).  
Our data also points to Type I IFN/IFNAR1 controlling disease 
tolerance to malaria. Tolerance is a defense mechanism, that does 
not limit pathogen load (38), and this is in agreement with recent 
studies that illustrate Ifnar1-/- mice providing a survival advantage 
against Plasmodium infection (39). As a side note, Type I 
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IFN/IFNAR1 signaling system can also be regulated by heme 
oxygenase-1, a stress-response enzyme associated with CM 
pathogenesis in children, as we previously reported (25).  
The development of a novel transfer protocol allowed focus on 
cellular mechanisms involved in ECM protection conferred by 
IFNAR1. These experiments uncovered that IFNAR1 in primed 
splenic CD8+ T cells is unequivocally needed to abrogate ECM 
resistance in Ifnar1-/- mice. The cytotoxic profile of CD8+ T cells in 
ECM induction has been shown using cell transfers, and identified 
perforin (40) and Granzyme B (41) as essential elements to 
produce cytotoxicity and effector CD8+ T cell responses. As we saw 
no hindrance in the cytotoxic profile of splenic Ifnar1-/- CD8+ T cells 
upon infection (Figure 3.7a-c), this suggests that priming in the 
spleen is not impaired. However, as we observed lower retention of 
activated CD8+ T cells in the brain of Ifnar1-/- ECM resistant mice, 
Type I IFN could influence ECM via its action in the brain. Type I 
IFN has been shown as critical in maintaining CD8+ T cells at the 
site of their effector function (42), this hints therefore that 
unresponsive Ifnar1-/- CD8+ T cells may have impaired ability at 
accumulating within the brain tissue. We question whether enabling 
accumulation of IFNAR1-CD8+ T cells in the brain, could generate 
enough power to trigger an ECM response? We noted Ifnar1-/- mice 
that received primed CD8+ splenocytes accumulated relatively low 
numbers of activated CD8+ T cells within the brain tissue, yet 
developed ECM (Figure 3.7g-i). This supports the hypothesis that 
induction of ECM in transferred mice was not due to CD8+ T cell 
accumulation, but rather by their expression of IFNAR1, allowing 
CD8+ T cells to become re-activated by Type I IFN within the brain; 
unleashing their cytotoxic effector capacity. 
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Evidence has also shown that CD8+ T cells require constant 
antigen presentation to remain at their effector site (43-45). Type I 
IFN has been shown to directly stimulate CD8+ T cell responses 
during antigen cross-presentation (46). Therefore resistance of 
Ifnar1-/- CD8+ T cells to induce ECM, could be due to their inability 
to respond to Type I IFN signals during antigen presentation within 
the brain tissue. Moreover, the exact nature of how CD8+ T cells 
are presented in the brain is still unknown. We hypothesize that 
IFNAR1 impacts upon CD8+ T cell stimulation at different stages of 
Plasmodium infection. We support the spleen as a primary site of 
parasite antigen presentation and propose that a secondary site of 
stimulation and presentation to CD8+ T cells occurs within the brain 
tissue. In fact, transfer of Ifnar1-/- CD8- splenocytes caused a slight 
increase in susceptibility to ECM, possibly reflecting the effect of 
other immune cells, prominently activated CD4+ T cells, in 
promoting ECM development (47), by an IFNAR1 independent 
mechanism. 
Ifnar1-/- mice have also proved fundamental in uncovering the 
therapeutic use of Type I IFN in cancer (48), and in cases of 
Experimental autoimmune encephalomyelitis (17). However in 
support of our results (45), reviews how Type I IFN therapy has led 
to the induction of auto-immune diseases. Our results tempt the 
notion that blocking IFNAR1 would be therapeutic for CM 
protection, however this would have to done with extreme precision 
due to the vast array of cells expressing IFNAR1, and more 
importantly this would not directly mimic an IFNAR1 gene 
polymorphism. 
Our work collectively highlights the cohesive role of IFNAR1 
during CM development, conferring human CM protection and as 
an implicator of CD8+ T cell pathology in mouse ECM. These 
! "#(!
observations allow us to speculate that the impact of IFNAR1 in 
human CM may operate through stimulation of CD8+ T cells. 
Together these results classify responses of Type I IFN through 
IFNAR1 as vital components in CM pathogenesis.  
3.6.1 Statistical Analysis 
Non-parametric Mann Whitney test was used for analysis 
when comparing two groups of mouse data. One-way ANOVA was 
used in comparing three or more groups of data. Survival analysis 
was assessed by Log rank Test; all performed using Prism 
GraphPad 4. *P " 0.05 was considered statistically significant. 
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This thesis work has shown through the development of a 
novel pre-sensitization protocol the essential role that type I IFN 
priming plays in CD8+ T cell mediated ECM induction. Our work on 
understanding the intrinsic properties of CD8+ T cell responses to 
type I IFN also suggests future experiments. Selective co-transfer 
experiments enabled information to be gained on understanding the 
necessary roles of type I IFN on surrounding cell types upon CD8+ 
T cell expansion. Preliminary results show that CD8+ T cells from 
C57BL/6 mice can be primed in an IFNAR1- environment and are 
still able to induce ECM in previously resistant Ifnar1-/- mice. This 
confirms that IFNAR1 expression on CD8+ T cells is critical in ECM 
induction.  
Future prospects for further exploration of type I IFN 
mediated CD8+ T cell properties in the context of malaria infection, 
could include the following aspects. As our work focused on day 
five post-infection for the time point of assessing T cell activation, 
supported by (Ferreira et al., 2011; Villegas-Mendez et al., 2011), it 
would be of interest to also assess a kinetics curve for proliferation 
of CD8+ T cells and investigate activation states, such as CD62L 
and CD44 expression, which would enable us to assess migration 
of CD8+ T cells from the spleen. This would allow us to ascertain 
timings of type I IFN action upon CD8+ T cells during innate and 
adaptive immune responses across infection, and highlight any 
defects in cell migration to the brain tissue site. 
Type I IFN also governs CD8+ T cell clonal expansion and 
memory differentiation (Aichele et al., 2006; Thompson et al., 
2006), with 5-10% of effector CD8+ T cells developing into memory 
T cells (Kolumam et al., 2005). Therefore we could explore in depth 
CD8+ T cell sub-populations upon parasite infection, and thus 
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determine whether type I IFN signaling affects expansion and 
differentiation.  
Further it is of specific interest to also evaluate expression of 
chemokines in Ifnar1-/- vs C57BL/6 CD8+ T cells and it is of interest 
to perform kinetic studies of entry and maintenance of CD8+ T cells 
within the brain tissue. 
In fact secondary memory CD8+ T cells, defined as 
repeatedly exposed to Ag, have increased expression of GrB and 
CTL activity, but show an exhaustive profile (Nolz and Harty, 2011; 
Ou et al., 2001), and have their capacity to kill worn out. This is an 
interesting idea that could warrant investigation in malaria 
infections, and would allow us to explore the different CD8+ T cell 
responses upon exposure to the parasite Ag at the spleen and 
brain site. This could be achieved by repeating our pre-sensitization 
step several times in wild-type mice and then scoring the power of 
CD8+ T cells to induce CM. Exhaustion of parasite specific CD8+ T 
cells could be monitored following CD8+ T cells activation status in 
the spleen and ultimately the exhaustion mechanism would offer an 
explanation for the high incidence of CM in young children. This 
would parallel to the accumulation of exhausted B cells and CD4+ T 
cells in individuals living in endemic regions of malaria infection 
(Illingworth et al., 2013), as a new concept to explain naturally 
acquired immunity.  
 
The use of Ifnar1-/- mice has proved essential in understanding 
the system of type I IFN during ECM. Ifnar1-/- mice are reported by 
The Jackson Laboratory to have increased susceptibility to viral 
infections, as well as higher levels of myeloid lineage cells and a 
reduced response to immuno-stimulatory DNA and 
Lipopolysaccharide (LPS) via the TLR pathway (Smith et al., 2005). 
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It was also found that genes dependent on the NF-%B pathway, c-
FLIP and iNOS, are further down regulated in the Ifnar1-/- mice 
(Huys et al., 2009). However as we saw increased proliferation of 
peripheral parasites within the Ifnar1-/- mice model during infection, 
presence of PbA and immune responses mediated through IL-10 
and TNF-& for example, in the brain tissue, in absence of ECM, we 
can infer that a dampened down immune response in Ifnar1-/- mice 
represents a tolerance mechanism during a parasite mediated 
infection. It remains to be determined at which level such effects 
are exerted and whether they are exclusively due to absence of 
IFNAR1 expression in CD8+ cells, which could be addressed by 
using mouse models with conditional deletions of IFNAR1 in 
specific cells populations, for example CD8+, CD4+ and DC, 
(Mizutani et al., 2012; Prinz et al., 2008). Thus, this raises the 
possibility that disease tolerance strategies (Gozzelino et al., 2012), 
can be achieved by deterring innate immunity mechanisms that 
enhance adaptive pro-inflammatory responses and impact on 
immune-mediated tissue destruction in malaria infections. 
 
! As we observed both presence and seemingly responsive 
IFNAR1- CD8+ T cells at both critical sites of malaria infection, 
spleen and brain, it is now of importance to exactly uncover where 
management of CD8+ T cells is lacking in the Ifnar1-/- mice shielding 
their pathogenic function. Of interest to us is the method by which 
CD8+ T cells are presented and carry out their pathogenic role 
within the brain tissue site during malaria infection. We began work 
into exploring the potential role of endothelial cells (EC) at this site 
and whether they could be targeted for APC ability. We hypothesize 
that parasite Ag could be presented by EC within brain 
microvasculature to CD8+ T cells. The close interaction between 
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CD8+ T cells and EC is suggestive as a site of Ag presentation, 
however this would require the ability of ECs to act as APC.  
Research has begun to examine the potential of EC as 
APCs (McDouall et al., 1996), showing that human umbilical EC 
can provide allogenic stimulation to CD8+ T cells, due to their 
expression of MHC-I molecules on resting EC, and furthermore EC 
have been previously classified as “semi-professional” APCs 
(Epperson and Pober, 1994). In malaria infections, the role of EC 
has mostly been focused on their expression of ICAM-1 and its role 
in sequestering CD8+ T cells within the micro-vessels; mice 
deficient in ICAM-1 are protected from ECM development (Sun et 
al., 2003). We believe that the role of EC during ECM needs to be 
shifted towards the perspective that EC may be one possible 
vehicle of Ag presentation to CD8+ T cells during CM pathogenesis 
in the brain tissue, something that has been suggested but never 
proved in ECM models (Wheway et al., 2013).  
Type I IFN has been shown to act upon human EC (da Silva 
et al., 2002; Erdmann et al., 2011; Mintzer et al., 1998), and as EC 
can produce type I IFN via STAT4 and 6 (Torpey et al., 2004), this 
shows their ability at producing and being responsive to type I IFN. 
As presence of type I IFN during PbA infection leads to up-
regulation of genes for Ag processing and presentation (Miu et al., 
2008), as well as up-regulation of components of the MHC I and II 
pathways during PbA infection (Hervas-Stubbs et al., 2011; Miu et 
al., 2008; Smith et al., 2005), this supports our hypothesis that in 
the context of malaria infection and type I IFN action, the EC could 
act as an APC within the brain tissue site of infection.  
We believe this mechanism of Ag presentation could occur 
through the phenomenon of cross-presentation. Type I IFN is 
critical in coordinating DC activation and response in T cell 
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stimulation (Montoya et al., 2002), and it was reported that DCs can 
process and present extracellular Ag via ‘cross-presentation’ 
(Bevan, 1976; Lundie et al., 2008). This hypothesis would enable 
us to explain a puzzling result we have obtained for IFNAR1- CD8+ 
T cells taken from the brain tissue. We see these cells express GrB; 
have migrated and accumulated in the brain tissue, (until day six 
post-infection); but no ECM pathogenesis is seen, as confirmed by 
no disruption of the blood brain barrier. A promising line of work 
would aim therefore to resolve whether deficiencies in Ag 
presentation are seen within Ifnar1-/- mice, and whether absence of 
IFNAR1 signaling in the context of Ag presentation results in CD8+ 
T cells not being maintained within the brain tissue or not being 
able to perform effector killing functions. Another interesting aspect 
worth to investigate are the possible mechanisms used by EC to 
acquire parasite Ag during infection. Furthermore as type I IFN has 
been shown to act directly on DC, leading to effective cross-
presentation of Ag, to Ag specific CD8+ T cells (Le Bon et al., 2003; 
Le Bon et al., 2001), this reinforces a role of type I IFN acting upon 
EC to enhance its APC function. 
4.1 Therapeutic targets for cerebral malaria  
 To date there are no therapies in action for specific 
treatment of CM. Work done by (Cabrales et al., 2010; Eisenhut, 
2012; Polder et al., 1991), has suggested therapies aimed at 
triggering vaso-dilation would reduce the vessel restriction and 
occlusion that causes CM development. Work has also focused on 
down-regulating the inflammatory response via neutralizing IP-10 
and IP-10-/- mice (ligand for CXCR3 chemokine), showed protection 
from development of ECM (Nie et al., 2009). TNF is also a dictating 
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factor in CM development, and has been targeted in CM therapy. 
However a clinical study for the use of anti-TNF on Gambian CM 
patients reported no effect for increasing survival (van Hensbroek et 
al., 1996).  
Outside of malaria infection, an FDA approved treatment for 
multiple sclerosis (MS) has aimed at inhibiting T cell egress from 
lymph nodes in the lymphatic circulation, as MS is aggravated by T 
cells within the brain micro-vessels (Hla and Brinkmann, 2011). 
This drug treatment therefore may pose a potential candidate in 
prevention of ECM. In fact a recent study in Ugandan children 
showed lower plasma levels of S1P – the designated drug target - 
in CM vs uncomplicated malaria cases (Finney et al., 2011).  
 This Ph.D. thesis work points to a great potential in inhibiting 
the action of type I IFN, via hindering signaling through the IFNAR1 
for CM protection. The action of type I IFN is vast, during both the 
innate and adaptive immune response, therefore silencing or 
shutting down the type I IFN response would need to be carefully 
co-ordinated. Manipulation of type I IFN actions has been proposed 
for beneficial outcomes (Smith et al., 2005). In fact, very recently 
clinical trials have found promising results for the inhibition of the 
IFNAR1 receptor in systemic sclerosis (SSc) patients (Wang et al., 
2013). Increased type I IFN activity is associated with pathogenesis 
of SSc and Systemic lupus erythematous (SLE), where over-
expression of type I IFN-inducible genes and plasmocytoid (p)DC 
are found in the skin and blood of patients  (Tan et al., 2006; Yao et 
al., 2009). Furthermore actual induction of SLE or SSc has been 
seen in patients receiving type I therapy for chronic viral hepatitis, 
(Crow, 2010; Solans et al., 2004). This provides early evidence that 
the zealous effects of type I IFN during host immune responses can 
be controlled. This negative action of type I IFN has been put to use 
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as a therapy in targeting apoptosis in relapsing-remitting multiple 
sclerosis. The action of type I IFN can lead to apoptosis of the 
immune cells involved in the pathogenesis (Badovinac et al., 2005; 
Dhib-Jalbut and Marks, 2010; Zula et al., 2011) and eliminate these 
causative cell types. Therefore if it would be possible in our hands 
to selectively inhibit action of type I IFN at time points during 
malaria infection, we could aim at inhibiting type I IFN action upon T 
cells and suppress CD8+ T cell mediated induction of CM 
pathogenesis.  
However in strong disagreement with the results of this 
Ph.D. work and this hypothesis, are the following papers by (Morrell 
et al., 2011; Vigario et al., 2007), who found that treatment with 
recombinant-IFN-' blocked type I IFN production which led to 
decreased iRBC engagement and entry into the brain, delaying 
onset of CM in PbA infection.  
Collectively these findings clearly reflect the plethora of 
actions type I IFN takes during immune responses, and how close 
these type I IFN therapeutic effects are in becoming harmful over 
protective. Together with the work presented here, these 
investigations definitely warrant future efforts for uncovering how 
IFNAR1 could be targeted for ECM protection in malaria infections, 
and how important selective cell candidates and tissue sites may be 
in this discovery.  
 
4.2 Final Conclusions 
 This work collectively supports the vital role of type I IFN in 
CM development. Figure 4.1 represents the final hypothesis of this 
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thesis work and the role that type I IFN governs over the key 
players in ECM development.  
 
 
 
Figure 4.1. The Role of Type I IFN - IFNAR1 signaling in CM. 
Type I IFN can be seen as a central part in building an immune 
response to parasite invasion in CM development. Dendritic cells 
(DC), Endothelial cells (EC) and CD8+ T cells all have the ability to 
produce and release type I IFN (blue dotted lines). In turn, during a 
primary immune response in the spleen, type I IFN can act upon 
DC (a) to allow them to present parasite Ag to CD8+ T cells (b), 
whilst in turn type I IFN can act on CD8+ T cells, priming them in 
preparation for secondary Ag presentation (c). In the brain tissue 
site, we propose type I IFN is vital in maintaining CD8+ T cells at 
effector site (d), mediated through CD8+ T cell expression of 
IFNAR1. Type I IFN may act upon EC, enabling APC capacity (e), 
which leads to presentation of parasite Ag to CD8+ T cells (f). The 
action of type I IFN on these cell types is mediated through their 
expression of IFNAR1.  
 
 
We propose that the novel protocol developed and explored in 
Chapter two be instrumental in future ECM research, and used as a 
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method for further individual cell type understanding of the 
mechanisms leading to ECM development.  
It is important to close this work with the initial data that led 
to the beginning of this thesis. We must always remember the 
relevance of the mouse model and these discoveries to the human 
cases of CM. This work supports primary findings of a role of 
IFNAR1 in CM susceptibility in human cases, and the work 
presented here now supports revisiting these cases of CM. 
Together this could uncover therapeutic targets and preventative 
measure of CM development for the many countries still harrowed 
by malaria infection.   
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Appendix One  
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Methods in Malaria Research 
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Figure S1. Transfer of non-exposed CD8
+
 C57BL/6 cells cannot 
induce ECM in Ifnar1-/-
-/-
 mice. (a) Ifnar1-/-
-/-
 mice that received 
total spleen cells (open squares) from C57BL/6 non-exposed mice; 
transfer control is represented by infected Ifnar1-/-
-/-
 mice that 
received no cell transfer (diamonds). (b) Ifnar1-/-
-/-
 recipient mice 
that received sorted CD8
+
 spleen cells (open squares) or sorted 
!"&)!
CD8-depleted spleen cells (open circles) from C57BL/6 non-
exposed mice; transfer control is represented by infected Ifnar1-/-
-/-
 
mice that received no cell transfer (diamonds). (c) Ifnar1-/-
-/-
 mice 
that received sorted CD8
+
 spleen cells (open squares) or sorted CD8
-
 
depleted spleen cells (open circles) from Ifnar1-/-
-/-
 mice. (n = 3-6 
mice per group, parasitemia; unpaired, two tailed t-test performed 
between CD8
+
 and CD8-depleted cell transfer recipient groups; 
*P ! 0.05, **P ! 0.01, survival curves; Log-rank Test). Each plot 
represents one of at least two independent experiments performed. 
Time window of C57BL/6 ECM manifestations is shadowed in 
survival plots.  
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Figure S2. Ifnar1-/-
-/-
 mice show no significant difference in 
CD4
+
 T cell numbers and activation profile compared to 
C57BL/6 mice upon infection. Total number of CD4
+
 T cells (a) 
and IFN-"+ CD4
+ 
T cells (b) in the spleen of non-infected (NI) and 
infected C57BL/6 and Ifnar1-/-
-/-
 mice. Mice were infected 1 # 10
6
 
PbA, analyzed on day 5 PI. (n = 3-5 mice per group, non-parametric 
two tailed Mann Whitney test; *P ! 0.05, **P ! 0.01). Data is 
representative of two independent experiments performed. 
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Figure S3. Ifnar1-/- CD8+ T cells show effector profile like that of 
C57BL/6 mice. 
Mean fluorescence intensity (MFI) of GrB+ on CD8
+
 T cells (a) and 
IFN-"+ on CD8
+ 
T cells (b) in perfused brains of infected and non-
infected C57BL/6 and Ifnar1-/-
-/-
 mice, infected 1 # 10
6
 PbA, on day 
6 PI when C57BL/6 displayed symptoms of ECM development. (n 
= 3-5 mice per group, unpaired, two tailed t-test; *P ! 0.05. Data is 
representative of three independent experiments performed. 
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